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Intratumoral immunotherapy. B16-F10 murine melanoma model
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Background: Cancer immunotherapy based on direct intratumoral
injection of immunomodulators has been established at the end of
19th century using Coley’s toxin. Our novel therapeutic strategy is
based on the intratumoral injection of optimized mixture of TLR ago-
nists, causing strong inflammatory infiltration. Infiltrating cells (mainly
phagocytes) are directed to artificially opsonized tumor cells covered
by phagocytosis stimulating ligands.
Materials and methods: Immunotherapy was tested using B16-F10
murine melanoma model. Inflammatory infiltration was achieved
using the mixture of resiquimod, poly(I:C), and lipoteichoic acid. Arti-
ficial opsonisation of tumor cells was elicited by mannan anchored
to cell membranes using a hydrophobic anchor. The course of tumor
infiltration was studied using flow cytometry. Cytotoxic effect of infil-
trating immune cells on opsonized tumor cells was studied in vitro.
Participation of acquired immunity was elucidated on the basis of
intracellular IFN-gamma production by lymphocytes.
Results: Optimized cancer immunotherapy based on the synergy of
TLR agonists with artificially induced tumor opsonisation resulted in
complete cure of 83% of mice with advanced melanomas. Moreover,
cured mice acquired resistance to retransplantation of tumor cells.
Applied therapy has a strong antimetastatic effect. In the first phase of
immunotherapy, granulocyte predominance was observed, followed by
involvement of acquired immunity.
Conclusions: Intratumoral immunotherapy initiated by innate im-
munity based attack followed by joining of mechanisms of acquired
immunity is a promising approach for future application in clinical
practice as compounds used are safe for humans.
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Assessing humanized mouse models for cancer immunotherapy
L. Loumagne, J. Mestadier, S. D’agostino, A. Rohaut, Y. Ruffin, V. Croize, O.
Lemaître, S. S. Sidhu
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Background: Preclinical models that can recapitulate a functional
human immune system are essential tools for the continued investigation© The Author(s). 2017 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeof novel immunotherapy approaches. In this regard, immunodeficient
mice offer a unique opportunity to reconstitute, at least partially, a hu-
man immune system together with human tumors to characterize immu-
nomodulator compounds in a more physiologically relevant setting. The
aim of this project was to perform a head to head comparison of several
highly immunodeficient mouse strains engrafted with human CD34+
Hematopoietic Stem Cells (HSCs) for their ability to develop and sustain a
multi-lineage engraftment of human immune cells. The most promising
mouse model(s) will then be assessed for their capacity to support
human tumor xenografts (CDX and PDX). Finally, we will determine if we
can elicit an immune response to selected immunotherapeutic agents to
drive anti-tumor activity.
Materials and methods: The mice strains analyzed are NSG, NOG,
NSG-SGM3, and NOG-EXL; the latter two being transgenic for the ex-
pression of human cytokines important in myeloid cell development.
Humanization was performed in-house by injecting human umbilical
cord blood CD34+ HSCs from different donors into the tail-vein of 4–5
week old female mice post-irradiation. To monitor human immune sys-
tem reconstitution, flow cytometry analysis on blood was performed at
approximately 4 week intervals beginning at week 4 post-injection of
human CD34+ HSCs. At week 18, a terminal analysis was performed,
consisting of a thorough immune cell profiling of blood, spleen and
bone marrow by flow cytometry. Tissues were collected for the immu-
nohistochemical staining of human immune cells and ex vivo func-
tional assays will be performed.
Results: Comparison of the immune system from different humanized
mouse models show that all strains display high levels of engraftment of
human CD45+ cells ranging from 50 to 70% at 18 weeks post-
humanization. Population such as T CD4+ and CD8+ as well as B cells are
well reconstituted and minor populations such as monocytes/macro-
phages, NK, and subsets of DC are also present at a lower percentage.
Complete results obtained from different mouse strains will be available
on the congress day.
Conclusions: Overall, this project will provide a head-to-head com-
parison of several humanized mouse models that will be of value in
the immunotherapy field according to the potent advantages of
these models and the paucity of studies directly comparing different
immunodeficient mouse strains.
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A predictive PD-L1*CD8 cell density score for NSCLC patients
treated with durvalumab
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Background: Current PD-1/PD-L1 checkpoint inhibitor based immuno-
therapies for advanced non-small cell lung cancer (NSCLC) showle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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image1 and data analysis of immunohistochemically (IHC) stained tissue
sections within the Tissue Phenomics methodology to determine
whether CD8+ and PD-L1+ cells densities could better identify patients
most likely to respond to durvalumab than using a manual PD-L1 scor-
ing of positive tumor cells (25% cutoff). Durvalumab is a human IgG1
monoclonal antibody that inhibits programmed death ligand-1 (PD-L1)
binding to programmed death-1 and B7.1/CD80, restoring antitumor
immunity2,3.
Materials and methods: CP1108/NCT01693562 was a nonrando-
mized phase 1/2 trial evaluating durvalumab in advanced NSCLC and
other solid tumors4. Digital slides from 163 baseline tumor biopsies,
IHC stained for PD-L1 (Ventana SP263) and CD8 (Ventana SP239),
were fully automatically scored with Definiens’ Developer XD 2.1.4
software using the product of PD-L1+ and CD8+ cell densities. The
image analysis results were quality controlled using ground truth
annotations provided by a panel of three pathologists. A discovery
set (n = 84) was used to identify the scoring algorithm and the cutoff
value, which was then tested on a validation set (n = 79). The robust-
ness of the scoring algorithm was pre-validated using Monte-Carlo
(MC) cross-validation.
Results: The most accurate and robust scoring method in terms of
MC performance metrics (positive predictive value, prevalence, pOS,
pPFS) was identified as the product of average CD8+ and PD-L1+
cells densities in the pathologist annotated tumor center. Patients
with high CD8*PD-L1 scores show significantly improved outcome
compared to the CD8*PD-L1 low subgroup (ORR: 0.39 vs 0.07, OS log
rank p-value: 0.0099 (training set) and 0.00053 (confirmation set)).
CD8*PD-L1 further appears to predict patients’ outcome better than
the PD-L1 status visually determined by pathologists (ORR: 39% vs
27%, median OS: 24.3 vs 17.8).
Conclusions: Although further validation studies are required, we ob-
serve that a scoring algorithm based on automated image analysis of
CD8+ and PDL1+ cell densities in baseline tumor biopsies improves
the stratification of NSCLC patients treated with durvalumab when
compared to visual histopathology scoring.
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Background: Cancer associated fibroblasts are known to highly inter-
act with infiltrating immune cells within the tumor microenviron-
ment. In this work, we investigate the influence of specific fibroblast
derived cytokines on the infiltration capacity of CD3 + CD8+ cytotoxic
T lymphocyte subpopulations using a multicellular 3D co-culture
System.
Materials and methods: 3D tumor microtissues were cultivated
using a hanging drops system. Human A549 and Calu-6 cancer cell
lines were incubated alone or together with the human fibroblast
cell line SV80 for 10 days to form microtissues. On day 10, periph-
eral blood mononuclear cells (PBMC) were added for 24 h. En-
dogenous cytokine expression of interleukin-2 (IL-2), IL-4, IL-5, IL-6,
IL-12p70, interferon gamma (IFN-γ) and tumor necrosis factor alpha
(TNF-α) in microtissue mono-, co- and tri-cultures was analyzed with
a multi-cytokine immunoassay. Subsequently, measured cytokineswere added to cancer cell/PBMC co-cultures to investigate the ef-
fect of these cytokines on infiltrating immune cell subpopulations.
Infiltrating subpopulations were investigated by flow cytometry.
Results: In both A549/SV80 and Calu-6/SV80 co-cultures and in SV80
monocultures, the cytokines TNF-α, IL-2, IL-5, IL-6 and IL-12p70 were
measured. Minimal or no concentrations of the investigated cyto-
kines were detected in cancer cell and PBMC monocultures. IL-4 and
IFN-γ were not measured in all approaches. Additional application of
the detected cytokines showed that IL-2 inhibited infiltration of naïve
T lymphocytes into cancer cell/PBMC co-cultures and enhanced
infiltration of differentiated T lymphocytes. Application of IL-5, IL-6
and TNF-α had only minor effects on infiltrating T lymphocyte
subpopulations.
Conclusions: We show that in multicellular cancer microtissues, can-
cer associated fibroblasts are a main origin of cytokines. Moreover,
we prove that IL-2 increases the infiltration of differentiated T lym-
phocytes. Targeting the interaction of T lymphocyte subpopulations
and cytokines derived from cancer associated fibroblasts might be a
promising strategy for future therapeutic approaches.
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Background: High-grade gliomas (HGGs) are one of the deadliest
cancers. In the last decade, immunotherapies have shown promising
results in preclinical studies; however, when translated into clinical
practice, they did not provide the expected outcomes. The low trans-
lational impact of animal models used in such preclinical studies is
one of the main causes of discrepancy. These models often lack a
well characterized glioma stem-cells (GSCs) compartment, which is
one of the major causes of immune escape and resistance to stand-
ard therapy. Moreover, the immune status of the animals has never
been characterized nor considered as a significant factor, despite the
well-known immunosuppression in HGG patients. The aim of this
study was to develop a new preclinical model of HGG, based on the
recent in vitro demonstration that neurosphere (NS) culture is effect-
ive in increasing the amount of GSCs in the CT-2A cell-line of murine
HGG. In this model, a special focus was given to GSCs and to the im-
mune status of the mice in order to overcome the above mentioned
limitations.
Materials and methods: CT-2A NS were established from standard
monolayer (ML) cultures. Orthotopic tumors were generated by in-
oculating the brain of C57BL/6 mice with 5000 CT-2A cells, derived
either from ML or NS cultures. The expression of stemness markers
(Oct3/4, Nestin and CD133) was evaluated with flow-cytometry and
immunohistochemistry in cell cultures and in brain tumors. Tumor
volume was assessed with 9.4 T MRI at serial time points. The im-
mune status of the mice was evaluated with cytometric bead array
of circulating cytokines known for promoting tumor growth (TNFal-
pha, G-CSF, IL-1B and CCL-2), or mediating the anti-tumor response
(IL-2 and IFNgamma).
Results: Flow-cytometry and immunohistochemistry showed a higher
expression of stemness markers in NS cultures compared to ML. This
difference persisted after in vivo inoculation of tumor cells: compared
to ML, NS tumors showed a higher expression of Oct3/4 (p < 0,01),
Nestin (p < 0,001) and CD133 (p < 0,05). NS tumors were more
Journal for ImmunoTherapy of Cancer 2017, 5(Suppl 1):12 Page 3 of 19aggressive than their ML counterpart, as they displayed higher mi-
totic index (p < 0,0001) and increased vascular proliferation (p <
0,001). As a consequence, mice inoculated with NS cells survived sig-
nificantly shorter (p < 0,005) and developed larger tumors (p < 0,01).
In preliminary experiments, changes were also found for circulating
cytokines. TNFalfa, G-CSF, IL-1B and CCL-2, which are increased in
HGG patients, displayed higher levels in NS tumors compared to ML
(42,6 vs 27,0 pg/mL; 63,1 vs 34,9 pg/mL; 39,0 vs 24,1 pg/mL; 111,8 vs
84,7 pg/mL). Similarly, the level of the anti-tumor immune response
cytokines in NS tumors was in line with what is observed in the clin-
ical setting: IL-2 increased (7,5 vs 4,1 pg/mL), IFNgamma decreased
(1,0 vs 2,0 pg/mL) in comparison with ML tumors.
Conclusions: This work represents the first demonstration that brain
tumors generated from CT-2A NS retain an enriched population of
GSCs; furthermore, these tumors induce in the host mice immuno-
logical alterations that closely mimic the clinical situation. This new
experimental platform offers a unique opportunity to study new im-
munotherapeutic approaches for HGGs, allowing to test their thera-
peutic effect on the GSC compartment in the context of the specific
immunological alterations which characterize HGG patients.
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Genomic profiling and in vitro screen of syngeneic mouse cell lines
testing checkpoint inhibitors in combination with targeted agents
in a coculture system with mouse T cells
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Background: Cancer immunotherapy has provided substantial clinical
benefits to patients with advanced diseases. In pre-clinical studies,
CrownBio has developed a large collection of syngeneic models to
facilitate in vivo efficacy testing of immune-oncology agents in mice
(MuScreenTM). To combine the ostensibly separate therapeutic strat-
egies of activating immune cells against and targeting the unique
genetic characteristics of a tumor model, we sought to thoroughly
characterize the mutation profiles of these syngeneic mouse cell lines
and examine drug response profiles of these cell line models. The
goal of this work was to provide an in vitro system in evaluating
combination effectiveness when targeting both immune checkpoint
markers and oncogenic targets in preclinical studies.
Materials and methods: We investigated mutation and gene expres-
sion profiles of 18 mouse cancer cell lines out of the 23 syngeneic
mouse models for 50 well defined cancer-related genes by RNAseq
(Illumina HiSeq X10). Next, we performed in vitro screen of the 18
syngeneic mouse cancer cell lines against aPD1 and aPDL1 anti-
bodies and a few targeted agents as single-agent to generate base-
line data of cell growth inhibition (IC50). Finally, we performed a
combination assay on the same panel of the 18 syngeneic mouse
cell models to examine synergistic effect of PD-1 and PDL1 blockade
with targeted small molecules in a co-culture system in the presence
of mouse T cells. An IncuCyte real-time imaging platform was used
to distinguish activities of T cells and tumor cells.
Results: The oncogenic mutations we identified among 30,690 vari-
ants in exonic regions of the 50 well characterized oncogenes and
tumor suppressors include ALK (3 - frequency, same for the rest),
BRAF (4), BRCA1 (7), BRCA2 (12), EGFR (3), ERBB2 (6), EGFR3 (2),
FBXW7 (10), FLT3 (12), HRAS (1), KRAS (8), NRAS (1), PDGFRA (11),
PTCH1 (9), PIK3CA (2), PTEN (6), RET (3), SETD2 (5), SMAD4 (3), SMO
(13), TRP53 (13), TSC1 (3), and TSC2 (10). All of these genetic alter-
ations are clinically actionable. The same set of genes were also sub-
ject to mRNA expression change analysis. The in vitro screen results
of the panel of mouse cell lines against aPD1 and aPDL1 antibodies
and chemo and targeted agents either as single agent or in combin-
ation, and the implications in preclinical studies, will be presented
and discussed.
Conclusions: The future for immune-oncology therapy is in undoubt-
edly combination therapy. The in vitro screen platform we established
here for syngeneic mouse cell lines in a co-culture system with mouseT cells allows quick and cost-efficient screen of checkpoint inhibition
agents either alone or with conventional chemo or targeted therapy.
Our future plan is to further expand the panel of well annotated syn-
geneic mouse cell models for the in vitro screen and compare in vitro
data with the results of corresponding in vivo studies (MuScreenTM).
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Doxorubicin increases TLR4 triggered activation marker on
dendritic cells independent of exCalcium and the inflammasome
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Background: Low dose chemotherapy alone or in combination with
immune checkpoint inhibitors is implemented in clinic routine cancer
treatment regimes. Thereby chemotherapy not only has a direct effect
on cancer cells but also has proven to indirectly activate the immune
system by ICD (immunogenic cell death) of cancer cells and to have dir-
ect effects on cells of the innate and adaptive immunity. Furthermore,
the success of ICD has been demonstrated to dependent on the ability
of DC (dendritic cells) to mount an inflammasome response. ExCalcium
has been shown to function as new DAMP (danger associated molecu-
lar pattern) activating the inflammasome when combined with TLR4
triggering signals. The ICD triggers immune cell activation by different
mediators, among them are ligands for TLR4.
Materials and methods: In this study we tested the direct effect of
Doxorubicin on activation marker (FACS) and IL-1 beta production
(ELISA) has hallmarks of effector responses of BMDC (bone marrow de-
rived dendritic cells) of wildtype, gprc6a ko (calcium receptor) and asc
ko (adapter essential for the inflammasome clustering) mice in vitro.
Results: Previously we identified a lack of response of chemotherapy
induced tumor control in vivo in gprc6a ko and asc ko mice. Here,
the in vitro data show a dose dependent robust (CD40 and CD86)
and minor (MHC class I and II) increase of expression on dendritic
cells when doxorubicin is combined with LPS in wildtype mice. Doxo-
rubicin has no effect on marker expression when added alone. The
increase on activation marker by doxorubicin is independent of IL-1
beta production, since no difference on secreted IL-1 beta was seen.
Interesting, doxorubicin does not lead to an IL-1 beta production on
it’s own or in combination with LPS, as has been suggested earlier.
The marked increase in activation marker expression on BMDCs upon
Doxorubicin is independent of gprc6a and asc as data revealed no
difference. Of note, BMDCs of asc ko mice do not mount an inflam-
masome response by TLR4 trigger combined with DAMP signals, still
the activation marker are highly regulated upon this trigger.
Conclusions: Hence, our in vitro data reveal an inflammasome and
exCalcium signal independent direct activation of dendritic cells by
chemotherapy that does not explain the lack of chemo-responsiveness
in gprc6a ko mice in vivo.
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Immunomodulatory Kits do not induce AML-blasts’ proliferation
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Background: AML-blasts can be converted to DCleu by immunomodu-
latory ‘Kits’ (ex vivo). T-cells’ anergy can be overcome after stimulation
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tion of blast-proliferation (e.g. by immunomodulatory Kit-application
in vivo) in AML-pts has to be excluded.
Materials and methods: 8 ‘Kits’ containing combinations of GM-CSF
with 1–2 additional factors (PGE-1/2, Picibanil, IFNɑ, TNFɑ, Calciu-
mionophore) were studied with respect to the generation of DC/
DCleu from blasts, mediation of antileukemic reactivity (after DC/
DCleu-stimulation) and with respect to their potential to induce
blast-proliferation in a whole blood (WB) culture-system. We stud-
ied 3 different markers (IPO-38, Ki-67, CD71) and quantified blast
proliferation before/after culture. We correlated findings with
(ex vivo) antileukemic functionality, with disease-entities and the
course of the disease.
Results:
DC-generation: We could generate DC/DCleu regularly from WB cul-
ture from 36 AML-pts.
Detection of blast proliferation: Ø65.6% (range46-82%) of uncul-
tured blasts expressed IPO-38, 33.1% (16-50%) CD71, 25.4% (8-43%)
Ki-67.
Induction of blast proliferation: Pooling all results we found lowest
amounts of proliferating blasts after culture with Kit I (GM-CSF +
Picibanil, 10% +/−13.32), Kit K (GM-CSF + PGE2, 9.14% +/−12.01), Kit
M (GM-CSF + PGE1, 7.67% +/−11.79). Amounts of proliferating blasts
were lower compared to uncultured cells. Highest expression of prolif-
erating blasts was found with IPO-38 followed by CD71 and Ki-67. We
found few individual AML-samples with increased blast-proliferation
after ex vivo Kit-culture.
Antileukemic activity: T-cells stimulated with DCleu (generated with
Kits) improved antileukemic activity. Correlations between blast-
proliferation and antileukemic activity will be presented.
Clinical correlations: Pts with bad (vs good) cytogenetic risk were
characterized by higher proportions of proliferating blasts in un-
cultured blasts; in some Pts with iron-deficiency anemia (IDA)
proportions of CD71 + uncultured blasts were lower than of IPO-
38/Ki-67+ blasts.
Conclusions:
IPO-38 is a stable marker to be used to quantify proliferating blasts
in AML-pts. CD71 is also a good marker, although not suitable for
some pts with IDA, Ki-67 is no reliable marker for every given pt.
Subtypes of pts correlated with proportions of proliferating blasts. In
general KIT treatment of blasts did only exceptionally induce blast
proliferation ex vivo. In general lowest risk for blast proliferation was
seen after culture with KIT I, K and M. T-cell-stimulation with DC/
DCleu generated after Kit-treatment resulted regularly in antileuke-
mic reactivity. We conclude that an in vivo treatment of AML-pts
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Background: Although regressing tumors are frequently associated
with a large immune infiltrate, the cellular interactions that govern
a successful anti tumor immunity remains elusive. Here, we have
triggered Interferon-type I signalling in a breast tumor model
(MMTV-PyMT) using DMXAA, a ligand of STING (a key detector of
cytoplasmic DNA and of viral infection).
Materials and methods: Mice with MMTV-PyMT tumors have received
a single intraperitoneal injection of DMXAA (23 mg/Kg) and we have
examined the dynamics of the immune response which takes place inthe tumor microenvironment during tumor regression. The tumor
vasculature was visualized by contrast-enhanced ultrasound. Selective
depletion experiments using antibody and inhibitor treatments in vivo,
together with dynamic imaging, allowed to characterize the cooper-
ation between immune cell subsets.
Results: We show that the disruption of the tumor vasculature and the
associated IFN alpha/beta release, conditioned a swift and massive re-
cruitment of neutrophils, followed by a delayed rise in CD8 T cells and
inflammatory monocytes in the tumor mass. All these immune cell sub-
sets contributed to the efficacy of tumor regression. In particular, we
show that neutrophils and monocytes were necessary for an optimal
CD8 T cell recruitment and activation. In return, monocytes get acti-
vated by infiltrating-CD8 T cells.
Conclusions: Altogether, these data highlight that type I interferon
signalling is crucial to bridge tumor detection and the initiation of an
efficient anti-tumor immune response. We provide evidence for de-
terminant interactions between myeloid cells and T cells that are
reminiscent of immune response controlling infections and strongly
suggest further developpment of strategies that mobilize and favor
cooperations between various immune cell subsets in the tumor.A10
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cells or whole blood from healthy volunteers or patients with AML
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Background: Dendritic cells (DC) and ‘leukemia-derived DC’ (DCleu)
are potent stimulators of various immunoreactive cells and play a
pivotal role in the (re-)activation of the immune system.
Materials and methods: We established a new protocol, containing
GM-CSF, IL-4, Picibanil and PGE1 (‘Pici2’), to generate DC/DCleu ex-vivo
from mononuclear cells (‘MNC-DC’) or directly from whole blood (to
simulate in-vivo conditions, ‘WB-DC’) from AML-patients. Further, we
analysed the DC-generating-potential of the ‘IMMUNOMODULATORY
KIT-M’ containing GM-CSF and PGE1. Results with regard to DC-, T-
cell-subtypes and mediation of antileukemic activity were compared
to an established DC-generating protocol (‘Pici1’ containing GM-CSF,
IL-4, Picibanil, PGE2) or to a culture without cytokines.
Results:1.) DC-generation: healthy-‘MNC/WB-DC’: We generated com-
parable DC-proportions with ‘Pici2’ and the standard protocol ‘Pici1’.
With ‘Pici2’ we significantly (p < 0.001) improved the DC-amounts
compared to controls without cytokines. AML-‘MNC-DC’: In contrast
to cases with ‘Pici1’, ‘Pici2’ performed a sufficient DC-generation
(≥10% DC) in every case. The amounts of DCleu were comparable
with both protocols. AML-‘WB-DC’: ‘Kit-M’ enabled a sufficient DC-
generation in >65% of cases. Further, we generated higher amounts
of DCleu with the two PGE1 containing ‘cocktails’ (DCleu: range: 3.4%-
13.6%) in comparison to controls without cytokines. 2.) Mature DC:
Adding PGE1 to the ‘DC-generating-cocktails’ increased the propor-
tions of mature DC (CD197+) in comparison to ‘Pici1’ in AML-samples.
This effect, however, did not occur in healthy-samples. 3.) T-cell-
subtypes: T-cell-stimulation with DC, generated with PGE1 containing
‘cocktails’, positively influenced the composition of T-cell-subsets,
characterised by higher proportions of proliferating (CD71+), non-
naïve (CD45RO+), central-(memory) (CD45RO+CCR7+) and effector-
(memory)T-cells (CD45RO+CCR7−). 4.) Antileukemic activity: T-cells
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proved antileukemic activity (‘blast lysis’) in >70% of cases.
Conclusions: We developed a new DC/DCleu generating protocol and
demonstrated that PGE1 is suitable for generating DC/DCleu in suffi-
cient amounts. These cells reliably (re-)activate immunoreactive cells
and improve the overall ex-vivo antileukemic activity. In-vivo trials
(animals and/or humans) have to be performed to study potential
effects of PGE1 in the mediation of antileukemic reactions in-vivo in
patients with AML.A11
Interleukin-22 (IL-22) does not influence methycholanthren-A-
mediated tumorigenesis
A. Markota, C. Ochs, P. May, A. Gottschlich, J. Suárez Gosálvez, C. Karches,
D. Wenk, S. Endres, S. Kobold
Divison of Clinical Pharmacology, Department of Internal Medicine IV,
Ludwig-Maximilians Universität, Munich, Germany
Correspondence: A. Markota
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Background: Interleukin-22 (IL-22) is a unique cytokine expressed by
immune cell subtypes such as T and NK cells and acting exclusively
on Interleukin-22-receptor-1 (IL-22-R1) positive epithelial cells. Re-
cently, we have demonstrated that expression of IL-22 is frequently
found in primary human small and large cell lung cancer samples. It
is also known that IL-22 is found at high levels in the primary tumor,
serum and in the malignant pleural effusion of non-small cell lung
cancer patients. However, the influence of IL-22 on the development
of a spontaneous experimental tumor remained unaddressed.
Materials and methods: To test the influence of IL-22 on tumorigen-
esis, we used the murine methylcholantren-A (MCA) model. MCA was
injected at different doses (100 μg, 200 μg and 400 μg) subcutane-
ously in wild type or IL-22-KO Balb/c mice. Tumor onset and growth
was monitored.
Results: The time of tumor development correlated with the dose of
MCA used. In wild type mice, 100, 200 and 400 μg of MCA led to a
median onset of tumor growth (first day of palpable lesion) at days
124, 83 and 70 respectively (n = 4 to 6 per group). IL-22-KO mice had
similar intervals until tumor onset of 131, 88 and 70 days, respect-
ively. Tumor growth after development was also similar between
MCA dosage groups. No difference in median overall survival was
noted in IL-22-KO (173, 161 and 164 days) versus wild type (163, 165
and 165 days) mice. We could not observe any impact of IL-22-KO
on the phenotype of mice developing sarcoma (weight or behavior).
Conclusions: Endogenous IL-22 does not appear to play a role in
MCA-induced sarcoma model in Balb/c mice. The findings in this
inflammation-based tumorigenesis model are in contrast to pub-
lished findings on enhancing tumor promoting role of IL-22 in the
APC-min colon cancer model.A12
Inhibition of CD39 and CD73 by 3rd generation antisense
oligonucleotides to improve immunity against tumors
T. Hilmenyuk, R. Klar, F. Jaschinski
Secarna Pharmaceuticals GmbH & Co. KG, Planegg/Martinsried, Germany
Correspondence: T. Hilmenyuk
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Background: During the last decades it became obvious that the
immune system can be utilized to evoke effective anti-tumor re-
sponses. However, cancer cells develop mechanisms to circumvent
this. The two ectonucleotidases CD39 and CD73 are promising drug
targets, as they act in concert to convert extracellular immune-
stimulating ATP to immunosuppressive Adenosine. CD39 and CD73
are expressed on different immune cells as well as on cancer cells.
Accordingly, in order to enhance immunity against tumors it would
be favorable to increase extracellular ATP- and to reduce Adenosine
concentrations in the tumor microenvironment.Materials and methods: We designed unformulated antisense oli-
gonucleotides (ASOs) with specificity for human CD39 (hCD39)
and CD73 (hCD73). ASOs were synthesized as GapmeRs with
flanking locked nucleic acid modifications to increase stability
and affinity to the target RNA. Knockdown efficacy of ASOs on
mRNA and protein level was investigated in cancer cell lines and
primary human T cells. CD39 activity was evaluated by measuring
ATP degradation in cell supernatants. We determined CD73 activ-
ity by quantification of free phosphate, released during the con-
version of AMP to Adenosine. As functional readout we analyzed
T cell proliferation and viability in presence of extracellular ATP
and Adenosine.
Results: Our initial experiments revealed, that CD39 was predom-
inantly expressed on activated CD8+ T cells whereas CD73 was
exclusively expressed on activated CD4+ T cells, suggesting that
both T cell populations work in concert to convert immune
stimulating ATP to immune suppressive adenosine. Furthermore,
we investigated a successful knockdown of CD39 and CD73 on
mRNA and protein level in cancer cell lines and primary CD4+
and CD8+ T cells after administering ASOs. Moreover, enzymatic
activity of CD39 and CD73 was blocked by ASO treatment.
Addition of extracellular ATP significantly impaired proliferation
and viability of CD39 expressing CD8+ T cells probably via the
formation of immunosuppressive ATP-degradation products. Strik-
ingly, administration with CD39-ASO but not with unspecific con-
trol ASO successfully reversed this inhibition. Extracellular AMP
strongly inhibited proliferation and viability of CD73-competent
CD4+ T cells most likely by the generation of immunosuppressive
Adenosine. Notably, CD73-ASO treatment protected CD4+ T cells
from proliferative inhibition. Our initial in vivo studies in mice ap-
plying mouse specific CD39-ASOs systemically demonstrated a
successful knockdown of CD39 mRNA expression in spleens and
lymph nodes. The impact of CD39- and CD73-ASO knockdown
in vivo on anti-tumor immune responses, tumor growth and sur-
vival will be subsequently analyzed in forthcoming studies.
Conclusions: Therefore, targeting CD39 and CD73 by ASOs repre-
sents a very promising state-of-the art therapeutic approach to im-
prove immunity against tumors.
A13
The immunome in early stage NSCLC: flow cytometry analyses of
immunological subpopulations in tumor, lung tissue and whole
blood
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Background: Immune checkpoint therapies have recently revolu-
tionized cancer treatment highlighting the crucial role of the im-
mune system in cancer. The prognosis and outcome is based on
subtype, location and function of various immune cells, includ-
ing T-lymphocytes, dendritic cells, but also the innate immune
system. To define patients with a high probability for response
and thus improve outcome and cost effectiveness, a proper
knowledge of immunological alterations is highly warranted. We
therefore investigate the immunome of early stage NSCLC pa-
tients in a prospective setting.
Materials and methods: Approval by the regional ethics board and
ICs were given. Whole blood (WB), tumor and adjacent normal tis-
sue of 40 early stage NSCLC patients were collected and single cells
suspension achieved via mechanical disruption and enzymatic di-
gestion. To characterize the cellular composition, differentiation
and activation status of immune cells, 9 color flow cytometry was
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ulations. Samples were analyzed on a FACS Fortessa using FlowJo
software. Significance (p < 0.05) was determined by Friedman tests
with Dunn’s multiple comparison analyses.
Results: Granulocytes were less frequent in tumor and normal tissue
compared to WB. As a consequence, proportion of lymphocytes
among leucocytes was significantly higher in lung and tumor tissues.
Regarding lymphocyte subsets, proportions of T cells and the major
CD4-, CD8- and γδTCR-expressing subsets were comparable in all
three compartments whereas B cells tended to be higher in tumor
and lower in lung tissue. Vice versa, proportion of NK cells was signifi-
cantly lower in tumor compared to normal tissue and WB, accompan-
ied by a lower CD158b (KIR2D) expression. In contrast, the inhibitory
receptor CD159a (NKG2A) was expressed in a higher proportion in the
tumor compared to both blood and healthy tissue. Naïve T cells were
nearly absent in lung and tumor tissue. CD4 T cells in tumor were
enriched for central memory cells, whereas in healthy tissue effector
memory cells prevailed. Compared to blood a higher proportion of
CD8 T cells expressed the early activation marker CD69 in normal tissue
and even higher in tumors. The chemokine receptor CD183 (CXCR3)
was expressed in tumor on a significantly larger subset of B cells than
in WB and lung tissue, indicating its involvement in the regulation of
migration of B cells to the tumor site. Our results underline changes in
the immunome to occur early in lung tumorgenesis and highlight the
importance of NK and B cell subpopulations. Therefore in addition to
immune checkpoint inhibition drugs that also target B cells and the in-
nate immune system are required.
Conclusions: We demonstrate changes in the immunome in early
stage NSCLC patients and found NK and B cells to be the most altered.
Further investigations concerning the functional and prognostic impact
of our results are warranted.
A14
Mitochondrial mass analysis in CD8+ T cells from lung cancer
patients
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Background: CD8+ T cells undergo major metabolic changes upon ac-
tivation, but how mitochondrial metabolism is altered in lung cancer is
still unknown. Malignant pleural effusions, which are infiltrated by lym-
phocytes and tumor cells, are frequent in patients with advanced
stages of lung cancer. Pleural effusion CD8+ T cells from lung cancer
patients show reduced effector functions which might be caused by a
deficient mitochondrial response.
Materials and methods: Pleural effusion or peripheral blood CD4+
and CD8+ T cells, from lung cancer patients and healthy donors, were
stimulated with anti-CD3 antibody or bead-coated anti-CD3 and anti-
CD28 antibodies for 24 h under normoxic and hypoxic (2%O2) condi-
tions. Then, mitochondrial mass was analyzed using MitoTracker Green
on CD8+ T cells by flow cytometry. Also, Nuclear Respiratory Factor-1
(NRF-1) protein levels were measured on purified CD8+ T cells by
immuno-PCR after anti-CD3 stimulation.
Results: Under non-stimulated conditions, mitochondrial mass, mea-
sured as Mean Fluorescence Intensity of Mitotracker Green, was higher
in pleural effusion CD8+ T cells compared with that of peripheral blood
CD8+ T cells from cancer patients and healthy donors. After stimulation
with anti-CD3 and anti-CD28 antibodies, memory CD45RA-CD27 + CD8
+ T cells from healthy donors reduced their mitochondrial mass; this
phenomenon was not observed in memory CD8+ T cells from lung
cancer patients. Moreover, after anti-CD3 stimulation under hypoxic
conditions, memory CD8+ T cells from peripheral blood reduced their
mitochondrial content, in both cancer patients and healthy donors. By
contrast, memory CD8+ T cells from malignant effusions were not able
to reduce their mitochondrial mass. In addition, NRF-1 levels were re-
duced in pleural effusion CD8+ T cells compared to those from periph-
eral blood from cancer patients and healthy donors. After anti-CD3stimulation, NRF-1 levels were increased in peripheral blood but not
pleural effusion CD8+ T cells from lung cancer patients.
Conclusions: Pleural effusion CD8+ T cells from lung cancer patients
did not modify their mitochondrial content and NRF-1 levels in re-
sponse to activation or hypoxia, which might compromise the me-
tabolism and function of these cells.
A15
Targeting hIDO1 with 3rd generation antisense oligonucleotides
for modulation of the tumor microenvironment
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Background: Targeting the immunosuppressive shield of tumors has
emerged as a promising treatment option for oncologic indications
in the last years. Especially the success of antibodies targeting CTLA-
4 and PD-1 in late stage melanoma patients paved the way for
immuno-oncology in daily clinical practice. However, despite long
lasting remissions in a small subset of tumor patients the majority of
patients does not respond to the currently available immunother-
apies. This is based on the fact that tumor cells and suppressive im-
mune cells can express a plethora of immunosuppressive factors
leading to immune evasion of the tumor. One of those factors is the
enzyme indoleamin-2,3-dioxygenase 1 (IDO1) which is a critical factor
in the metabolism of tryptophan. The degradation of tryptophan in
the tumor microenvironment leads on the one hand to tryptophan
starvation and on the other hand to the generation of kynurenines
both resulting in a suppression of immune effector cells.
Materials and methods: We designed antisense oligonucleotides
(ASOs) with specificity for human IDO1 (hIDO1). ASOs were synthe-
sized as GapmeRs with flanking locked nucleic acids to increase sta-
bility and affinity to the target RNA. The knockdown efficacy of ASOs
on the mRNA and protein level was investigated in cancer cell lines
and primary human cells after ASO treatment without addition of a
transfection reagent. The effect of hIDO1 knockdown on the produc-
tion of L-Kynurenine was determined by measurement of the L-
Kynurenine concentration in cell culture supernatants by ELISA.
Results: We tested the mRNA knockdown efficacy of a number of
ASOs in two cancer cell lines, namely EFO-21 and SKOV-3. Strikingly,
a subset of ASOs resulted in a hIDO1 mRNA knockdown of >90%.
The IC50 values were determined in EFO-21 cells which resulted in
the selection of two highly potent ASOs with IC50 values in the low
nanomolar range for further experiments. The treatment of cancer
cell lines as well as primary human cells resulted in reduction of IDO
protein levels by >85%. Importantly, we observed a complete block
in the production of immunosuppressive L-Kynurenine in ASO
treated cells and IC50 values in the low nanomolar range.
Conclusions: We designed highly potent hIDO1 ASOs that efficiently
knock down hIDO1 mRNA and protein and block the production of im-
munosuppressive kynurenines in cancer cell lines as well as primary hu-
man cells. We are furthermore investigating the effect of hIDO1
knockdown in cancer cell lines and dendritic cells on the function of T
cells and NK cells in vitro at the moment. Experiments proving the effi-
cacy of IDO1 ASOs in syngeneic tumor models are ongoing using
mouse-specific ASOs. Taken together, we developed an innovative im-
munotherapeutic tool to block the expression of hIDO1 that will poten-
tially improve treatment options for cancer patients in the future.
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the abdomen before causing symptoms. This immediately explains that
mortality (which is the case in 80% of patients) is caused by the metas-
tases. So far, research concerning the immune system in ovarian cancer
has focussed on the tumor microenvironment. The peripheral immune
landscape in ovarian cancer remains largely undiscovered.
Materials and methods: Peripheral blood mononuclear cells were col-
lected prospectively in 39 patients with invasive ovarian cancer. Samples
were prelevated at diagnosis, after cytoreductive surgery ((interval-
)debulking), after three courses of (neo-)adjuvant platin-based chemo-
therapy, and at the end of their primary treatment. Fluorescent activated
cell sorting was applied to detect immunostimulatory cells (Thelper cells
(CD4+), Tcytotoxic cells (CD8
+), natural killer cells (NK)) and immunosuppres-
sive cells (regulatory T cells (Treg), mMDSC (monocytic myeloid-derived
suppressor cells), gMDSC (granulocytic MDSC)).
Results: Patients were distributed as follows: 76% had an advanced
stage of the disease at diagnosis (stage III and IV), 44% relapsed, in-
cluding six deaths. Tumors had a high-grade histology in 80% of
cases. Stage IV ovarian cancers presented with higher amounts of
mMDSC (p 0.007). High-grade ovarian cancers presented with more
PD1+MDSC (p 0.03) (PD1 = programmed cell death protein 1). After
primary treatment (i.e. chemotherapy and debulking surgery) there
was an increase of Tcytotoxic cells (p 0.002) and activated Tcytotoxic
cells (CD8+CD69+)(p 0.02). Debulking surgery increased the number
of activated Thelper cells (CD4
+CD69+)(p 0.02). Progression free survival
was significantly reduced in case of increasing amount of Thelper
cells (p 0.02), activated Thelper cells (p 0.002), activated Tcytotoxic cells
(p 0.01), mMDSC (p 0.03) and PD1+mMDSC (p 0.002). Overall
survival was reduced in case of increasing activated Thelper cells
(p 0.04) and activated Tcytotoxic cells (p 0.04).
Conclusions: In contrast to what is seen in literature in the primary
tumor, a high presence of Thelper cells and Tcytotoxic cells in the systemic
circulation of ovarian cancer patients is correlated with a worse survival.
It almost seems that the systemic immune system represents a state of
immune alert of the body as a reaction to widespread metastatic
disease but that this is insufficient. mMDSC seem to be an important
immunosuppressive player in ovarian cancer.
The authors would like to thank the Olivia Hendrickx Research
Foundation for their support.
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Background: Ovarian cancer is considered a highly aggressive tumour,
killing still 80% of patients. So far immunotherapy trials have yielded
poor results, due to severe immunosuppression. Myeloid derived
suppressor cells (MDSC) are a heterogeneous group of immature mye-
loid cells that have a strong immunosuppressive function. MDSC can
be subdivided into monocytic MDSC (mMDSC) and granulocytic MDSC
(gMDSC) based on the relative surface expression of lymphocyte anti-
gen 6 complex locus C (Ly6C) and Ly6G in mice and cluster of differen-
tiation 14 (CD14) and CD15 in humans.
Materials and methods: The murine experiments were performed in
C57BL/6 mice (n = 30) and Rag1tm1Mom mice (n = 12), inoculated intraperi-
toneal (ip) with 5 × 106 ID8-fLuc cells. Mice received ip injections with
phosphate buffered saline (PBS), PBS liposomes or clodronate liposomes
twice weekly starting from tumor inoculation. Six mice per group were
evaluated for survival analysis. Three and four weeks after tumor chal-
lenge three mice per group were sacrificed for immune-monitoring on
ascites and serum. Immune cells were characterized by fluorescent acti-
vated cell sorting (FACS), cytokines were determined by cytometric beadarray (CBA). Next, peripheral blood mononuclear cells were collected pro-
spectively in 39 ovarian cancer patients at diagnosis. MDSC were defined
by FACS as live CD11b+HLA-DR− cells.
Results: Mice treated with clodronate liposomes died significantly faster
compared to immunocompetent mice (p = 0.004), whereas the survival
was not altered in mice lacking T- and B-cells (Rag1tm1Mom). After treat-
ment with clodronate liposomes we observed a significant decrease in
macrophages (p = 0.001). mMDSC (live CD11B+Ly6CHi) increased signifi-
cantly (p = 0.004) after treatment with clodronate liposomes. In patient
samples, we observed a significant decrease in progression free survival
in patients with a high number of CD14+ mMDSC (p = 0.03).
Conclusions: The administration of clodronate liposomes significantly
reduced survival of mice with ovarian cancer, most likely due to a de-
pletion of macrophages and a significant increase in mMDSC. This is in
accordance with the situation in ovarian cancer patients, where increas-
ing mMDSC are correlated with decreasing progression free survival.
The authors would like to thank the Olivia Hendrickx Research Fund
for their support.
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Background: Preclinical models indicated that both, type I and type II
IFN, response gene expressions are relevant for the induction of a tumor-
ablative cytotoxic T cell induction. Furthermore, GBP1 expression in pri-
mary colorectal tumor cells was previously shown to be a prognostic fac-
tor. Therefore, we investigated the correlation between GBP1 and MxA in
colorectal liver metastasis (CRLM), tumor infiltrating lymphocytes and re-
currence free survival after surgical resection and overall survival.
Materials and methods: 24 colorectal cancer patients with surgically
treated liver metastasis were included in the study between 2005 and
2011. Immunohistochemical labeling of GBP1, MxA, Ki67, CD45RO, CD3
and CD8 was performed on formalin-fixed paraffin-embedded histo-
logical sections. Stainings were semiquantitatively scored for both tumor
specific and stromal expression. Median follow-up time was 1300 days.
Results: Tumor cell specific GBP1 expression was present in 63% of
the cases. The majority of tumors displayed MxA positivity to a vary-
ing degree. Intratumoral infiltration of CD3+ or CD8+ lymphocytes
was found in 16% and 26% of tumors, respectively. Importantly, both
CD3+ and CD8+ lymphocytic infiltration was associated with GBP1
expressing tumor cells of CRLM. GBP1 positive tumors tended to
have a lower Ki-67 labeling index, however, Ki-67 showed no prog-
nostic power for overall survival. In contrast, GBP1 expression was a
significant prognosticator for overall survival and showed a tendency
for predicting recurrence-free survival. MxA expression did not show
prognostic power or correlation with infiltrating lymphocytes. The
presence of intraepithelial CD8+ tumor infiltrating lymphocytes was
mostly found in long-term surviving patients.
Conclusions: Tumor cell specific GBP1 expression in CRLM is associ-
ated with CD3+ and CD8+ lymphocytic infiltration and with overall
survival. Thus, we propose that in future clinical studies exploring
novel immunotherapeutic approaches in colorectal cancer the GBP1
expression should also be evaluated.
A19
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lation of immunosuppressive cells of myeloid lineage. Recently,
MDSC were studied in the context of tumour growth, where they are
responsible for the tumour escape from the host immune surveil-
lance via the mechanism of inhibition of CD8+ T cells and by promo-
tion of angiogenesis and metastatic spread. In several types of
cancer, increased number of MDSC correlated with worse prognosis
and mortality. MDSC can be classified as granulocytic (Gr-MDSC) and
monocytic (Mo-MDSC). Here we evaluate circulating Mo-MDSC in
non-cancer individuals and examined whether Mo-MDSC are in-
creased in breast and colorectal cancer patients.
Materials and methods: We measured Mo-MDSC counts in periph-
eral blood of non-cancer individuals representing the control group
(N = 61), and breast cancer (N = 39) and colorectal cancer (N = 52) pa-
tients. MDSC were detected as CD45 + CD11b + CD33 + CD14 + HLA-
Drlow/- and quantified as proportion (%) of MDSC in total white blood
cells and as an absolute count. Two-sample two-tailed Mann–Whit-
ney U Test was used to examine differences in Mo-MDSC between
control and cancer groups and Wilcoxon signed-rank test was used
in paired sample comparison of the Mo-MDSC at the time of diagno-
sis vs at the time of follow-up.
Results: In the control group, the Mo-MDSC count was gender- and
age-independent, with the average of 0.073 × 109/l and 1.09%. Breast
cancer patients, both count and proportion of circulating Mo-MDSC
was significantly higher (p < 0.001) compared to the control group
with average levels of 0.229 × 109/l and 3.57%, respectively. In breast
cancer patients, we observed increase in Mo-MDSC number after the
administration of granulopoietic growth factors. Compared to control
group, colorectal cancer (CRC) patients had significantly higher count
and proportion of circulating Mo-MDSC with average values of
0.125 × 109/l, 1.71%. Number of Mo-MDSC did not correlate with
tumour clinicopathologic stage, localization (colon vs. rectum), side
(left vs. right) and microsatellite instability (MSI). During 6-month
follow-up of 19 CRC patients, we observed increase in Mo-MDSC ab-
solute counts and proportion in 74% patients, and decrease in 11%
patients.
Conclusions: Colorectal cancer patients at diagnosis showed higher
counts of circulating Mo-MDSCs, possibly due to immunosuppressive
effect of the tumour microenvironment. The change in Mo-MDSC
count from baseline needs to be evaluated in the context of CRC pa-
tient outcome. Recombinant granulopoietic growth factors increase
number of circulating Mo-MDSCs and the effect of this phenomenon
on breast cancer prognosis remains to be elucidated.
Supported by Ministry of Health of Czech Republic via grant nr.16-
31966A and by MEYS-NPS I - LO1413.
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Background: The tumor microenvironment (TME) is the intersec-
tion between tumor cells and surrounding non-transformed cells.
It contains immune cells, signaling molecules, stromal and extra-
cellular matrix. The tumor microenvironment is often promoting
tumor growth during all stages of carcinogenesis. However, the
function and regulatory mechanism of each constituent is still
poorly understood. Recent studies show that T cell checkpoint
therapy provides durable and therapeutic results for non-small
cell lung cancer (NSCLC). The presence of PD-L1 is a promising
marker to predict positive response. Current IHC methods to
measure PD-L1 are subjective and highly variable. A higher-
throughput and standardized method that can systematically
measure gene expression of cells present in the TME has emerged
to be a more desirable solution.Materials and methods: We applied the OncomineTM Immune
Response Research Assay to measure the expression of 395 genes in
NSCLC research samples from 40 matched FFPE and fresh frozen
sample types. This assay covers genes involved in checkpoint path-
way, T cell regulation, cytokine and interferon signaling pathways,
and markers of different tumor infiltrating lymphocyte TIL subsets, as
well as tumor markers. With an input requirement of 10 ng of total
RNA, libraries were generated, templated on the Ion ChefTM and
sequenced on the Ion S5TM System. Sequencing data was analyzed
and mapped with Torrent Suite Software and differential expression
analysis was conducted with AffymetrixTM Transcriptome Analysis
Console.
Results: Our data showed that gene expression profiles can stratify
NSCLC FFPE samples by histopathology and TIL levels. The expres-
sion profiles of FFPE and fresh frozen samples are highly correlated
with an average correlation greater than 0.9. Approximately 80% of
the 40 samples show moderate to high expression of CD8+ T cell cy-
tokines, IFNG and TNFa. We conducted a differential expression ana-
lysis between a group of samples (n = 8) with high percentage of
surrounding and infiltrating lymphocytes and another group (n = 5)
with low stromal content but devoid of infiltrating lymphocytes. We
found a large number of genes which annotated as infiltrating
lymphocyte markers (CTSS, CXCR4, CD37, SRGN, FCER1G, SAMHD1,
and GZMA) are significantly up-regulated in samples with high per-
centage of surrounding and infiltrating lymphocytes. The expression
of 22 genes in the panel was validated with qPCR using FFPE sam-
ples. These genes cover a range of low, medium, and high expressors
according to our NGS data. There is a strong correlation (R > 0.9) be-
tween NGS and qPCR data.
Conclusions: In summary, this study highlights the robustness of
using a targeted panel to understand the composition and regula-
tory mechanism of the TME and tumor immune response. For re-
search use only. Not for use in diagnostic procedures.
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Background: Adenosine (ADO), apotent inhibitor of T-cell activation,
is generated within the tumor through coordinated and sequential
cleavage of extracellular adenosine triphosphate (ATP) by the ecto-
nucleotidases CD39 (which produces adenosine monophosphate,
AMP) and CD73 (which hydrolyzes AMP to ADO). Whereas a number
of anti-CD73 antibodies are being advanced into clinical trials, to
date there have been only a few reports of potent and selective
small molecule CD73 inhibitors, such as those described here.
Materials and methods:Enzymatic assays:Ecto-nucleotidase activity
was determined by calculating the amount of inorganic phosphate
(malachite green assay; absorbance at 620 nm) produced after 50-
min incubation with 25 μM AMP or ATP, in the presence of varying
concentrations of test compound(s). The following systems were
used. Endogenous expression: hCD73/SKOV-3 cells; mCD73/E771
cells. Stable over-expression: hCD73/CHO; hCD39/CHO. Transient ex-
pression: mCD73/CHO; NTPDase2/CHO; NTPDase3/CHO; NTPDase8/
CHO. Immune Function Assays: CD8+ T cell assays: Human CD8+ T cells
were isolated from buffy coats and pretreated with CD73 inhibitor or
a control compound for one hour. Afterwards, the cells were acti-
vated (anti-CD2/CD3/CD28) in the presence of 50 μM AMP and
10 μM ADO deaminase inhibitor (EHNA). In some experiments, ex-
ogenous recombinant human IL12p70 was added to the culture. Fol-
lowing 3 days, activation (CD25) and effector functions (Granzyme B
and IFNγ) were measured by flow cytometry. Tumor model: CT26 and
B16F10 cells were subcutaneously implanted into 8 week old Balb/c
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150 mm3, therapeutic dosing using 30 mg/kg A000830 s.c., q.d. was
initiated. αPD1 was dosed at 5 mg/kg (B16F10) or 10 mg/kg (CT26)
q3d. To analyze tumor infiltrating leukocytes, single cell suspensions
were generated from tissues, blocked and stained with the appropri-
ate antibody cocktails.
Results: A series of potent and specific small-molecule inhibitors of
human and mouse CD73 has been generated, represented by
A000830 and A001421, that inhibit the enzymatic activity of human
and mouse CD73 with high selectivity against a large panel of related
and unrelated enzymes. In an in vitro human CD8+ T cell activation
assay employing primary human and mouse CD8+ T cells, both
A000830 and A001421 robustly reversed ADO mediated inhibition of
CD25 expression as well as production of Granzyme B and IFNγ. Fi-
nally, in vivo dosing of A000830 in a monotherapeutic setting re-
sulted in limited tumor growth in a CT26 model and to an increased
therapeutic effect of αPD1 blocking antibody in a B16F10 model.
Tumor growth inhibition in the presence of A00830 and α-PD1 was
likely due to increased intra-tumoral ratios of CD8+ T cell to Treg or
MDSC.
Conclusions: We describe a novel class of potent and selective small-
molecule CD73 inhibitors that block the generation of ADO from
extracellular AMP, restore ADO-mediated inhibition of human and
mouse T-cell activation in vitro, and display promising anti-tumor ac-
tivity in vivo.
A22
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Background: Colorectal cancer (CRC) is one of the most frequently
diagnosed cancers worldwide. The number of the new cases, espe-
cially in developing country, is predicted to climb over the following
decades. Altered cancer metabolism has been shown to promote
sustained tumorgenesis and the survival of cancer cells under ex-
treme environment. Glutathione represents an important source of
energy for tumor cell metabolism. Thus, we hypothesize that the
tumor metabolic phenotype of glutathione could be prognosistic fac-
tor in CRC patients.
Materials and methods: We retrospectively investigated 120 pairs of
cancerous and matched noncancerous tissue specimens from CRC
patients who underwent the same standard chemotherapy and rad-
ical surgery. We stained the successive paraffin-embedded slides for
those marker involved in glutathione metabolism (GSTM3, GSTP1,
SRM, ODC1) respectively and correlate the expression of these
markers with tumor grade, stage, overall survival (OS) and
progression-free survival (PFS). We further integrated transcriptome
data of 345 CRC patients from public geo database and investigated
the correlations.
Results: Expression of GSTM3 in tumor group are decreased than
in matched noncancerous group, while GSTP1, SRM and ODC1
are overexpressed in tumor group. Moreover, within the tumor
group, combined higher expression of GSTP1, SRM and ODC1
had lower 5-year PFS (52%) and OS (58%) than those with lower
GSTP1 tumor group (60% and 66%, respectively; PFS HR:
1.89,95% confidence interval(CI): 1.21-3.40, P = 0.019; OS HR: 2.34,
95% CI: 1.38-4.32, P = 0.021). While, higher expression group of
GSTM3 within tumor group has higher 5-year PFS (70%) and OS
(72%) than those with lower GSTP1 tumor group (65% and 66%,
respectively; PFS HR: 2.1,95% confidence interval(CI): 1.4-3.21, P =
0.0059; OS HR: 2.03, 95% CI: 1.32-4.17, P = 0.021).
Conclusions: The expression pattern of these marker are also cor-
related with OS and PFS of the patients. Thus, enhanced status
of glutathione metabolism could be a useful prognostic factor in
CRC patients.A23
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Background: Targeted immunotherapies (TIs) can selectively impair
the cancer evasion of immune surveillance. Phase II/III clinical trials
with CTLA-4 and PD-1/PD-L1 immune checkpoint inhibitors are at-
tractive therapeutic strategies in gastric cancer (GC) patients. The
Cancer Genome Atlas Research network recently proposed a four-
tiered molecular classification of GC, that could help to guide optimal
selection of therapy. Epstein-Barr virus (EBV) positive and microsatel-
lite unstable (MSI-high) GC are two molecular subtypes of particular
interest for TIs and are frequently associated with the morphologic
features of gastric cancer with lymphoid stroma (GCLS). The abun-
dant immune infiltrate and molecular features of GCLS offer an at-
tractive landscape to study tumour immune micro-environment,
immune checkpoints and their relationship with GC cells. The aim of
this study was to analyse clinico-pathological profile, EBV infection,
MSI phenotype, tumour immune microenvironment and PD-L1 status
in GCLS.
Materials and methods: Twenty-four GCLSs were analysed by: RNA
in situ hybridisation for EBV (EBER), PCR/fragment analysis for
MSI, immunohistochemistry (IHC) for cytokeratin (CK) AE1/AE3,
CD3, CD8, double immunofluorescence (IF) for CK/PD-L1 and
CD68/PD-L1 and PD-L1 copy number alteration. PD-L1 immunore-
activity was evaluated in tumour epithelial and stromal immune
cells, applying the Immunoreactivity Scoring System (IRS), as re-
cently described. Double IF was performed in selected cases (IRS
≥7). CD3+, CD8+ T cell densities and CD8/CD3 ratio (CD8/CD3R)
were calculated in the tumour centre (TC) and at the invasive
front (IF) by digital analysis. A tissue microarray was constructed
from a control group of 54 non-GCLSs and analysed by IHC for
PD-L1 and by EBER.
Results: GCLSs included 16 EBV+/MSS, 4 EBV-/MSI-high and 4 EBV-/
MSS cancers. Overall, CD8/CD3R at the IF exceeded CD8/CD3R in the
TC (p < 0.001). CD8/CD3R was significantly higher (p = 0.008) in EBV+
than in EBV- GCLSs. PD-L1 immunoreactivity was observed at the cell
membrane of tumour epithelial cells (IRS > 2) in 8/24 GCLSs and in
immune stromal cells (≥1%) in 22/24 GCLSs. 3/17 cases harboured
PD-L1 amplification (IRS > 2, n = 3/3), 11/17 a normal PD-L1 status and
3/17 PD-L1 hemizygous status (IRS > 2, n = 3/14). IRS > 2 and PD-L1
amplification were restricted to EBV+ (6/16) and MSI-high (2/4)
GCLSs. By comparison with non-GCLSs, GCLSs were more fre-
quently EBV+ (p < 0.001), PD-L1+ (p = 0.04) and harboured a dis-
tinctive clinico-pathological profile: younger age (p = 0.03), upper
location (p = 0.04), indeterminate histological subtype (Laurén
classification) (p < 0.001), less advanced pTNM stage (p = 0.002)
and better overall survival (p = 0.01).
Conclusions: GCLSs are characterised by distinctive clinico-
pathological features, EBV infection (66.7%), high CD8/CD3R (at
the IF and in EBV+ cases) and PD-L1 expression (33.3%). In keep-
ing with the recent molecular data, PD-L1 expression (IRS > 2)
and gene amplification were restricted to EBV+ and MSI-high
cases, reinforcing the potential implications of immunotherapy in
these molecular subtypes of GCLS.
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Background: Targeting immune checkpoints represents a promising
immunological treatment strategy in oncology. CD95 (APO-1/Fas) is a
member of the Tumour Necrosis Factor Receptor Super Family and
its corresponding ligand CD95 ligand (CD95L) is frequently overex-
pressed in cancers and tumour-associated endothelia. Binding of
CD95L to CD95 triggers activation-induced apoptosis in immune
cells, making CD95 a putative immune checkpoint. Asunercept
(APG101) is a fully human fusion protein consisting of the extracellu-
lar domain of CD95 and the Fc-domain of an IgG, which has been
confirmed as a potent inhibitor of CD95L signalling. Here we exam-
ined the mode-of-action of Asunercept in protection of immune cells
from activation-induced cell death and subsequent effects on tumour
cell killing.
Materials and methods: Monocytes isolated from healthy-donor
blood samples were differentiated in vitro into either M1- or M2-like
macrophages. Subpopulations were analyzed for lineage-markers
and cleaved-PARP by multi-colour flow cytometry following apop-
tosis induction by CD95L exposure. Analogous experiments were
performed using PBMCs and purified T cells. Apoptosis induction in
tumour cells and immune cells was also measured using a fluoro-
genic Caspase 3/7 substrate. Primary human microvascular endothe-
lial cells treated with various cytokines were used as a trans-well
invitro model of immune cell infiltration. Real-time cell analysis was
performed on direct co-cultures of activated T cells and monocyte-
depleted PBMCs with various tumour cell lines.
Results: M1- and M2-like macrophages express specific surface anti-
gens, including CD95, following activation and differentiation of
monocytes in vitro. Exposure of macrophages to soluble recombinant
CD95L induces apoptosis in both populations, although higher sensi-
tivity of M1- compared to M2-macrophages is observed. This is
consistent with higher expression of CD95 on M1-like macrophages.
Addition of APG101 protects macrophages from CD95L-induced cell
death in a dose-dependent manner, but does not interfere with
differentiation. Similar results were obtained after treatment of
monocyte-depleted PBMCs with CD95L and APG101. Transendothe-
lial migration of activated immune cells under immunosuppressive
conditions was enhanced in the presence of APG101. Finally, in
tumour killing assays using direct co-cultures of CD40-primed Ramos
B cells and polyclonal T cells, tumour killing was not impaired by
APG101, suggesting that primary anti-tumor killing mechanisms are
CD95L-independent.
Conclusions: Asunercept (APG101) is a potent inhibitor of pro-
apoptotic CD95/CD95L signaling in immune cells and protects acti-
vated immune cells from activation induced cell death AICD. Protec-
tion of T cells with Asunercept may enhance effector T cell migration
into tumours and, importantly, anti-tumour activity induced by direct
interaction between T cells and B cells is not compromised by
Asunercept. The inhibition of tumour-induced CD95L-mediated apop-
tosis of immune cells represents an attractive and novel concept for
immunotherapeutic treatment of tumours and the combination of
Asunercept with co-stimulatory TNFR-SF agonists is currently being
investigated.A25
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Background: It is well known that T cells recognize mutated antigens
in tumor cells. However, little is known about the ability of the im-
mune system to recognize self-antigens, like Her2, a protein that is
frequently overexpressed by breast cancer cells and against which
therapeutic monoclonal antibodies are used in the clinic.
Materials and methods: We evaluated, in peripheral blood of HLA-
A2+ breast cancer patients and healthy donors, the phenotype and
number of Her2 peptide KIFGSLAFL (E75)-specific T cells. For this, cir-
culating T cells were labeled with an E75-loaded HLA-A2 tetramer
and analyzed by flow cytometry.
Results: Her2-specific T cells were detected in all healthy donors (490
± 158/106 cells; n = 20). Cancer patients had significantly more Her2-
specific T cells (825 ± 380/106 cells; n = 20; p = 0.03). No difference was
observed in the median fluorescence intensity of the tetramer staining,
an indirect measurement of TCR affinity. Interestingly, patients with
Her2-overexpressing tumors had lower numbers of Her2-specific T cells
when compared to patients with luminal B tumors that do not overex-
press Her2 (Luminal B: 1532 ± 662/106 cells, n = 10; Her2: 529 ± 89/106
cells, n = 7; p = 0.01). When compared to healthy individuals, cancer pa-
tients had lower percentages of naïve (CD45RA+CCR7+) Her2-specific T
cells (p = 0.05), but also lower numbers of naïve T cells, regardless of
their specificity (p = 0.0002). Curiously, in patients, Her2-specific T cells
were more frequently naïve than what was found overall in the same
patient. This could be due to a tumor-specific T cell activation hin-
drance or to tumor-specific T cell recruitment.
Conclusions: Healthy and breast cancer patients have Her2-specific T
cells, but with different frequency and phenotypic patterns, a
phenomenon that should be further investigated to allow better re-
sults with Her2-based immunotherapy, e.g. vaccination with E75 pep-
tides. Financial Support: FAPESP-2014/25988-1.
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Background: Breast cancer, which accounts for 13.8% of all cancer
cases, remains the most common cancer and leading cause of cancer
deaths in European women. Despite the improvements in patient
outcome that have been achieved by earlier detection and thera-
peutic advances, disease continues to recur in many patients. At least
in part, recurrence and therapeutic resistance could be influenced/
predicted by tumour-related immunoregulatory events, and herein
we examined the immunological phenotype in the periphery of pa-
tients with breast cancer.
Materials and methods: The profile of natural killer (NK) and immu-
noregulatory cell subsets in the peripheral blood of patients with
breast cancer was determined by flow cytometry, as was the influ-
ence anthracycline chemotherapy on cell subset distribution in a
sub-set of patients. Immune gene transcript profiles were determined
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negative breast cancer (TNBC).
Results: Significantly increased levels of circulating immunoregula-
tory T (Treg) cells and myeloid-derived suppressor cells (MDSCs) were
present in the periphery of patients with cancer, and levels were
positively associated with tumour burden. Treg cells from patients
displayed a more suppressive/activated phenotype, as assessed by
the co-expression of ICOS and CD39. The percentage of HLA-
DRnegCD11b+CD33+ cells expressing CD15 was also greater in pa-
tients. Furthermore, levels of ‘classical’ monocytes (CD14+CD16−)
were lower, but levels of ‘intermediate’ monocytes (CD14+CD16++)
significantly higher in patients, with the phenotypic differences
correlating with disease stage. No differences in the frequency of
non-classical monocytes (CD14+CD16+) or the distribution of mono-
cyte subsets in mono+ TNBC patients between patients and healthy
controls were observed. The phenotypic profiles strongly correlated
with the transcriptomic data. The percentage of NK cells and the
proportion of the primary NK cell subsets (CD56dimCD16+ and
CD56brightCD16−) in breast cancer patients and controls were not
significantly different. Chemotherapy induced a significant decrease
in the total B cell and increase in the monocyte count, whereas it
had no effect on Treg and MDSC numbers. Chemotherapy also had
no effect on NK cell counts, but induced a general increase in the
expression of inhibitory and a decrease in the expression of activat-
ing receptors. Immune gene expression profiling demonstrated that
three out of 12 patients with TNBC over-expressed genes related to
monocyte/macrophage functions.
Conclusions: Although further detailed analyses in broader cohorts
of patients with breast cancer are warranted, phenotypic profiling
and immune gene transcript analysis of peripheral blood mono-
nuclear cells have the potential to inform clinical decisions and help
to predict therapeutic response.
A27
Digital pathology - a key to discover new biomarkers?
C. Geppert, A. Hartmann
Institute of Pathology, Erlangen, Germany
Correspondence: C. Geppert
Journal for ImmunoTherapy of Cancer 2016, 5(Suppl 1):A27
Background: The rapid growth of digital pathology in recent years
opened the doors to new image analysis applications which have be-
come an effective tool for biomarker discovery. This work wants to
give an overview over the digital pathology workflow in a research
application and possible approaches for image analysis. It will also
introduce a novel method to increment the accuracy and robustness
of the results in a reasonable time, based on pre-aligned images that
help to automate a part of the analysis that is still largely manual
and less objective today. This automation can lead to significant
speed ups of the process and reproducible results. It can also help
research organizations to deal with the growing lack of qualified
pathology staff by reducing the workload of their team and help
them focus on their core tasks.
Materials and methods: The proposed method is based on a pat-
ented image registration technology that enables the highly accurate
alignment of high resolution image data. A key application of this
method in biomarker discovery is the analysis of slides stained with
different histochemical dyes. A first study is conducted on metasta-
sizing melanoma in the context of personalized tumor therapy based
on e.g. the PD1 antibody: The immune response against the tumor is
a key indicator for the success of individualized patient treatment. To
assess the immune response, specific cell groups are quantified using
immunohistochemistry (IHC) markers and digital image analysis. A
cohort study of >100 patients will reveal the necessary cut-offs to
identify a new marker. In particular, IHC stains are created to mark T-
cells, cytostatic T-cells, leukocytes, and tissue of the melanoma
tumor, all on different sections. Using image registration, the sections
are spatially aligned to each other and a region of interest (depicted
in IHC stain for melanoma tumor tissue) is automatically transferred
to all other sections.Results: Following this process yields a significant speed-up, and
assures a high level of interobserver agreement. Results are more
objective and transparent and can be controlled completly by the
digital workflow. It can serve also as a strong routine tool in research
quality controll.
Conclusions: In conclusion, this work will give an outlook on how
digital pathology contributes not only to the discovery but also to
patient stratification, companion diagnostics like the immune re-
sponse and to deliver personalized medicine.
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Background: Breast cancer is one of the most common malignancies
among women worldwide. This represents about 12% of all new can-
cer causes and 25% of all cancers in women. The microRNAs (miR-
NAs) are post-transcriptional regulators of gene expression and their
degradation is involved in tumorigenesis. miR-708 down-regulates
proliferation and metastasis of ovarian cancer cells through the
glucocorticoid receptor (GR) activation and LSD1 modulation in
breast cancer cells. However, the induction of miR-708 via GR in
breast cancer remains largely unclear.
Materials and methods: Human breast cancer cell lines MCF-7 and
MDA-MB-231 were subjected to investigate proliferation and metas-
tasis under synthetic and natural GR agonistic agent dexamethasone
(DEX) or antcin A (ATA), respectively. Colony formation assay, im-
munoblotting, immunofluorescence and real-time PCR were used to
determine protein expression and localization. Luciferase reporter
assay was performed to monitor the transcriptional activation of cor-
responding transcriptional factors.
Results: In this study, we found that induction of miR-708 by GR
agonists DEX and ATA down-regulate proliferation and metastasis
of breast cancer cell lines. Further studies suggested that GR-
mediated induction of miR-708 inhabits COX-2 expression through
the suppression of NF-κB transcriptional activation, which is largely
involved in tumor cell proliferation. In addition, GR agonists DEX
and ATA significantly inhibited tumor cell metastasis via suppres-
sion of matrixmettaloprotenases.
Conclusions: The present study indicate that GR-mediated induction
of miR-708 may function as a tumor suppression gene in breast can-
cer development and miR-708/NF-κB axis may be a therapeutic inter-
ventions for breast cancer.
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Introduction: Tumour necrosis factor receptor superfamily (TNFR-SF)
proteins are widely expressed by immune and tumour cells
highlighting their importance in multiple locations and phases of the
anti-tumour immune response. Agonistic stimulation of certain mem-
bers of the TNFR-SF is considered to have a positive impact on
immunotherapy-based concepts in clinical oncology. Apogenix has
developed a proprietary technology platform for the construction of
novel hexavalent TNFR-SF agonists (HERA) for the treatment of can-
cer. As a result of the molecular design, each molecule is capable of
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to many agonistic anti-TNFR-SF antibodies (e.g., anti-TRAIL-R2 or anti-
CD40), signaling induced by HERA-ligands in vivo is independent of
additional crosslinking by Fc-γ receptors. The HERA engineering con-
cept has been successfully applied to TRAIL, CD40L, LIGHT, GITRL,
OX40L, 4-1BBL and CD27L resulting in hexavalent agonists suitable
for further development.
Methods & Results: CD27-Ligand (i.e., CD70) is a potent co-
stimulatory molecule that drives T-cell activation and survival
through interaction with its receptor (CD27). Here we show in vitro
and in vivo data for HERA-CD27L, a hexavalent CD27 agonist. HERA-
CD27L was expressed in CHO suspension cells and subjected to a
lab-scale production process, including affinity chromatography and
SEC-based polishing, resulting in homogenous aggregate-free protein
lots. The purified protein binds its respective target-receptor with
high affinity as determined by ELISA and biosensor measurements. In
vivo stability/PK studies have been performed in addition to in vitro
experiments with primary human and mouse lymphoid and myeloid
cell populations. Specifically, HERA-CD27L was able to bind CD27
expressed on primary human CD4+ and CD8+ T-cells and import-
antly, binding significantly increased T-cell expansion following acti-
vation. In vivo, the efficacy of HERA-CD27L was evaluated in the
colorectal syngeneic murine tumour models MC38-CEA and CT26. In
both models, HERA-CD27L treatment resulted in a dose dependent
tumour growth inhibition.
Conclusion & Outlook: In summary, the data on the hexavalent
HERA-CD27L demonstrate biological activity in the T-cell compart-
ment and confers potent immune cell-driven anti-tumour efficacy
in vivo. Our data suggest that HERA-CD27L can be applied as a
single agent or in combination with immune-checkpoint inhibitors.
Combinations of HERA-CD27L with other co-stimulatory ligands of
Apogenix’ HERA technology platform are in preclinical evaluation.
In addition, the CD95L antagonist Asunercept (APG101) represents
a novel putative checkpoint inhibitor for combinatorial treatment
with CD27L co-stimulation.
Therapeutic modulation and
monitoring of immune response
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Background: Syngeneic tumor models have been revived as an ef-
fective platform, with immunotherapy becoming a research focus of
oncology reagents development over the past several years. The
widely used in vitro cell-based screens which could quickly identify
responsive cells and assess PD effects, often fail in the development
of immunotherapeutics, due to it targeting the complex host im-
mune system. Alternatively, a large collection of syngeneic models
with well-characterized immunotherapy panel is established to inves-
tigate PD and efficacy, but may be cost prohibitive.
Materials and methods: Leveraging in-house syngeneic models and
its detailed profiling data, including treatment response of anti PD-1,
PD-L1, CTLA-4, OX-40, GITR, LAG3 and TIM3 antibodies, RNAseq data
on tumor samples, and FACS analysis on both baseline and post-
treatment tumor samples, we created the first in vivo screening panel
for immunotherapy: MuScreen. MuScreen, a 3 month screening with
up to 20 well-characterized syngeneic models, including both PD
and efficacy arms to be selected by the researchers based on results
observed from a large dataset. Test agents from multiple clients are
pooled together for each run (sharing vehicle and other common
groups) providing a significant reduction in the number of animals
used and the associated costs.
Results: CrownBio has established the first well-characterized in vivo
panel for immunotherapy. With the three MuScreen runs, we havegenerated new data on common immune checkpoint inhibitors (e.g.
aPD-1 antibody) and combination treatments. Base on the data of
RNAseq, FACS analysis, IHC and efficacy, a bioinformatics analyses
are further explored to identify the makers/pathways that could be
correlated with the efficacy or PD effect of the tested IO treatment.
Conclusions: MuScreen, a large in vivo syngeneic model panel, be-
comes a useful tool for cancer immunotherapeutics, provides rapid
screening of IO regents and may help on biomarker discovery in a
cost and time efficient manner.
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Background: Immune checkpoint inhibitors directed against pro-
grammed death-1 (PD-1) and cytotoxic T lymphocyte antigen-4
(CTLA-4) can provide long term benefit to a subset of cancer pa-
tients. Optimal patient selection remains challenging. Using serum
mass spectrometry, we have developed a predictive test associated
with prolonged survival of patients on anti-PD-1 therapy. Refinement
of the test defined a subgroup of patients with particularly poor sur-
vival. Analysis of protein set enrichment analysis (PSEA) generated
several hypotheses about the biological processes associated with
the tests.
Materials and Methods: MALDI mass spectra were generated from
pretreatment serum samples from 119 patients with metastatic mel-
anoma (MM) treated with nivolumab at the Moffitt Cancer Center. A
classifier development platform optimized for creation of multivariate
molecular diagnostic tests which can generalize well to independent
datasets was employed to create a test that identified patients with
prolonged overall survival. This test classified samples into two
groups: group 1 with prolonged survival and group 2 with short sur-
vival. The classifier was validated using two independent cohorts of
MM patients receiving anti-PD-1 agents: 30 patients from Yale Uni-
versity (YU) and 25 patients, most treated with pembrolizumab, from
Massachusetts General Hospital (MGH). The test was also applied to
pretreatment sera collected from 21 patients from Yale that received
combination PD-1/CTLA-4 blockade. The difference in outcomes be-
tween patients in group 1 and group 2 were assessed using log-rank
p values and Cox proportional hazard ratios (HRs).
Results: Of the 119 patients used in the test set, 34 (29%) were clas-
sified as group 1. Group 1 had longer overall survival (OS) and
progression-free survival (p = 0.002, p = 0.014 respectively), with two-
year survival of 67%. Thirteen patients (43%) from the Yale cohort
and eleven patients (44%) from the MGH cohort were classified as
Group 1. In the combined analysis of validation sera sets from pa-
tients receiving anti-PD-1 agents, patients classified as Group 1 had
better OS than Group 2 (p < 0.0001, HR = 0.162); their two–year sur-
vival was 86%. Within the cohort of patients receiving combination
PD-1/CTLA-4 blockade, 13 (62%) were classified as Group 1. Two-year
survival was 83% in Group 1 and 63% in Group 2. Further refinement
of the test identified patients who had either better and worse out-
come among those classified as Group 2. The difference appears to
be related to proteins associated with Th1 versus Th2 mediated im-
munity in these patients.
Conclusions: A serum proteomic test identified a subgroup of pa-
tients with prolonged survival with anti-PD-1 therapy. High two-year
survival in the Group 1 cohort may indicate that the test has poten-
tial utility in identifying patients who derive significant benefit from
anti-PD-1 monotherapy and might gain little benefit from the
addition of an anti-CTLA-4 agent. Further stratification of patients
Journal for ImmunoTherapy of Cancer 2017, 5(Suppl 1):12 Page 13 of 19classified as Group 2 identified patients who can benefit from treat-
ment from PD-1 monotherapy. Follow-up was 2 years for OS, and the
numbers in the validation set are small, indicating that further valid-
ation is necessary. Detection of biological differences in sensitivity
and resistance using PSEA methods applied to mass spectral data
suggest potentially important lines of further investigation.
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Background: iNKT/NK/CIKcell (subsets) are important for immune-
surveillance. Antibody ‘6B11’ targets the Vα24Jα18invariant-Tcell-
receptor (TCR) in the CDR3-region, which is semi-invariantly rear-
ranged in iNKTcells.
Materials and methods: We characterized I.) iNKT/NK/CIKsubsets
in PB-samples from healthy donors(n = 9), AMLpts(n = 23),
ALLpts(n = 20) and CLLpts(n = 21) in acute disease-stages and cor-
related findings with prognosis; II.) iNKT/NK/CIKsubsetsunder
stimulation with Dendritic-Cells of leukemic origin (DCleu), gener-
ated from AMLblasts in mononuclear cells(MNC) and whole-
blood(WB, containing soluble/cellular components of pts’PB) with
‘cocktails’ (DC-generating-methods/Kits).
Results: I.1) Compared to healthy MNC (significantly) lower propor-
tions of iNKTcells (6B11+/6B11+CD3+/6B11+CD161+), NKcells(CD3
−CD56+/CD3−CD161+) and CIKcells (CD3+CD56+/CD3+CD161+) were
found in MNC from AML/ALL/CLLpts. I.2) Subtyping of iNKTcells re-
vealed (significantly)higher proportions of CD3+Tcells and CD161
+NKcells in AML/ALL/CLL expressing 6B11 compared to healthy MNC.
I.3) Prognostic evaluations showed higher proportions of iNKT/NK/
CIKcells in prognostically favorable AML-subgroups (allocation to
younger age, primary disease-status, no extramedullary disease,
achievement and maintenance of CR after induction-chemotherapy).
Comparable correlations were seen in adultALL and CLLpts. II.1) We
quantified iNKT/NK/CIKsubsets before/after mixed-lymphocyte-
cultures (MLC) of T-cell-enriched immune-reactive cells stimulated
with MNC/WB (with/without pretreatment ‘cocktails’ inducing blasts’
conversion to DCleu) from AML-pts. Our findings show, that 1)iNKT/
NK/CIKcells increase after MLC independent of the stimulator-cells-
suspension (under the influence of IL-2); 2)Pretreatment of MNC/WB-
blasts’ with ‘cocktails’ increases iNKT-counts and induces a shift in
the composition of iNKT-/NK-/CIK-subsets after MLC, that might
correlate with an improved antileukemic potential; 3)INDIVIDUAL
samples showed varying, however higher iNKT, CIKcellcounts after
pretreatment with different (especially prostaglandin-containing)
‘cocktails’; 4)DC/iNKT/NK/CIKcells-values after MLC were comparable
in physiological hypoxia/normoxia; 5)In cases with antileukemic
blast-lytic activity after MLC T/iNKT/NK/CIKcells were significantly
increased - pointing to an involvement of these cells in antileukemic
reactions.
Conclusions: 1) Healthy MNC present with significantly higher iNKT/
NK/CIKcells compared to AML/ALL/CLL-leukemic MNC. 2) Subtypes of
iNKT-cells differ in healthy/leukemic samples, resembling a shift in the
composition of iNKT-cells. 3) Amounts of iNKT/NK/CIKcells in AML/ALL/
CLL-MNCsamples correlate with prognosis. 4) ‘Cocktail’treated AML-
blasts (resulting in DCleu) lead to a shift in T,iNKT/NK/CIKcellcounts/com-
positions, what correlates with improved antileukemic activity
against AMLblasts- pointing to a cross-talk of these cells. Propor-
tions of iNKT/NK/CIKcells (based on 6B11/CD161/CD56/CD3-antibodies)should regularly be evaluated in AML/ALL/CLL-diagnosis-panels for
quantitative, qualitative/prognostically relevant estimation of individual
pts’ antileukemic potential in detail and to learn about their role in DC/
DCleutriggered-immunesurveillance.
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Background: Nivolumab showed superior efficacy and survival com-
pared to docetaxel as a second line treatment of non-small cell lung
cancer. An expanded access program is ongoing in South Korea. We
observed efficacy and toxicity of nivolumab and correlation with
immunohistochemical(IHC) status of programmed death ligand-1(PD-
L1) expression.
Materials and methods: We prospectively enrolled 10 patients with
non-small cell lung cancer after failure of at least one line of prior
systemic treatment. Cases with tissue slides, IHC stain for PD-L1 was
performed with IHC 22C3 using pharmDx platform (Dako®) which is
being used for pembrolizumab trial.
Results: Six patients with squamous cell carcinoma and 4 patients
with adenocarcinoma were enrolled with male/female ratio of 5/5
and mean age of 63.8 years old. Nivolumab was used with a second,
third, fourth, fifth and six line of treatment in 4, 3, 1, 1, 1 cases, re-
spectively. IHC stain was performed in 5 cases and only 1 of them
showed positive staining for PD-L1. In response evaluation after
8 weeks of treatment, there was no case showing remission, but 8
cases showed stable disease and 2 cases showed progressive disease.
There was no serious adverse event except two cases with
hypothyoidism after nivolumab treatment. Nivolumab was discontin-
ued in 5 cases, and treatment is ongoing in the rest of cases. Median
progression free survival from the start of nivolumab treatment is
112 days (95% confidence interval, CI: 40 ~ 183 days). Median survival
was 175 days (95% CI: 131 ~ 218 days).
Conclusions: With these small number of cases who were heavily
treated before this trial, nivolumab showed limited efficacy and poor
correlation between efficacy and PD-L1 expression status. However,
toxicity was minimal and further evaluation of more clinical experi-
ence is warranted.
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Background: Anti-CTLA4 ipilimumab is now part of the clinical prac-
tice of advanced malignant melanoma treatment. However, only
about 20% of treated patients experience a durable response, the
medication is pricey and all treated patients are at risk of toxicity.
The identification of patients who are most likely to experience
clinical benefit is desired. Purpose of this study was to evaluate
candidate baseline peripheral blood biomarkers predicting clinical
outcome following ipilimumab treatment in advanced melanoma
patients.
Materials and methods: Overall survival (OS) of a total of 51 patients
with advanced malignant melanoma treated with ipilimumab at Masaryk
Journal for ImmunoTherapy of Cancer 2017, 5(Suppl 1):12 Page 14 of 19Memorial Cancer Institute, Brno, Czech Republic was evaluated in the
context of baseline routinely available peripheral blood biomarkers
(LDH, CRP, relative lymphocyte count, absolute monocyte count, abso-
lute eosinophil count). Statistical analysis was performed using survival
analysis. Survival probability was estimated by Kaplan-Meier method. A
difference between survival curves was assessed by log-rank test and
hazard ratio (HR) was calculated, Differences at p-value < 0.05 were con-
sidered to be statistically significant.
Results: All patients were treated with ipilimumab after its registra-
tion approval (55% within expanded access program) in standard
dosing. Median age was 61 years, 31 (61%) were female. Thirty-five
(69%) individuals were stage M1c, 6 (12%) M1b, and 10 (20%) M1a.
Median OS (mOS) after start of treatment was 17.3 months (95% CI
11.3; 25.9 months). The number of involved organs (0-or-1 vs. 2-
and-more) at the treatment initiation was not predictive for clinical
outcome. Absolute monocyte count and absolute eosinophil count
were not predictive for clinical outcome. For lactate dehydrogen-
ase, the optimal cut-off value distinguishing responders and non-
responder was 5 microkat/l with mOS 19.8 months in patients with
LDH <5 microkat/l and 3.5 months in patients with LDH ≥5 micro-
kat/l (p < 0.0001, HR = 22.1, 95% CI 6.6-73.8). In low LDH subgroup,
2-year survival was 40% and 3-year survival 34%. For C-reactive pro-
tein, the optimal cut-off value was 20 mg/l with mOS 19.0 months
in patients with CRP <20 mg/l and 3.2 months in patients with CRP
≥20 mg/l, (p <0.0001, HR = 12.9, 95% CI 4.3-39.0). In low CRP sub-
group, 2-year survival was 36% and 3-year survival 31%. For relative
lymfocyte count, the optimal cut-off value was 0.15 with mOS
19.0 months in patients with RLC ≥0.15 and 3.2 months in patients
with RLC <0.15, (p <0.0001, HR = 9.6, 95% CI 3.4-27.8). In low CRP
subgroup, 2-year survival was 35% and 3-year survival 31%.
Conclusions: Baseline routine peripheral blood parameters such as
elevated LDH, elevated CRP and low relative lymfocyte count are
strong predictors of overall survival in advanced malignant mel-
anoma patients treated with ipilimumab. Stratification according
to LDH level provided the strongest prediction of response to
ipilimumab.
Supported by by MEYS-NPS I - LO1413.
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Background: Non-small cell lung carcinoma (NSCLC) is the most fre-
quent type of lung cancer. Within this group, lung adenocarcinoma
is the most prevalent histological type. Treatment of patients diag-
nosed with advanced lung adenocarcinoma, whose tumors have no
activating epidermal growth factor receptor (EGFR) mutations, re-
mains in platinum-based double chemotherapy for four to six cycles.
High Mobility Group Box-1 (HMGB1) is an essential activator of cellu-
lar response to genotoxicity induced by cisplatin, due to HMGB1
binds to cisplatin-DNA-adduct favoring DNA repair and chemoresis-
tance. In contrast, some authors have reported that during cell death
induced by platinum-based compounds, HMGB1 is released. In the
extracellular space, HMGB1 acts as a damage-associated molecular
pattern (DAMP). HMGB1 in association with other molecules released
by stressed cells stimulate the anti-tumor immune response. In the
present study, plasma HMGB1 concentrations from a cohort of lung
adenocarcinoma patients with no activating EGFR mutations were
quantified during treatment with conventional chemotherapy, and
HMGB1 changes were associated with overall survival (OS).
Materials and methods: From 100 lung adenocarcinoma patients,
plasmas were collected at the start and during distinct cycles oftreatment. HMGB1 concentrations were quantified using a commer-
cial ELISA kit. An extended Cox model was used to examine the rela-
tionship between HMGB1 plasma fluctuations and OS.
Results: The Cox regression analysis revealed that HMGB1 plasma con-
centration was significantly associated with OS in a multivariate and
univariate models (p = 0.00094, hazard ratio = 0.69 and confidence
interval = 0.56-0.86). The patient group that increased plasma HMGB1
concentrations showed higher OS compared to that of the other group.
Results were confirmed by Kaplan-Meier survival curves.
Conclusions: During treatment, patients with a higher OS increased
significantly plasma HMGB1 levels. The increase of plasma HMGB1, in
the cohort of patient, could be due to tumor mass mainly contains
malignant cells with a high sensitivity to cisplatin treatment. Our data
suggest that, in NSCLC patients treated with conventional chemo-
therapy, the increase of HMGB1 plasma concentration could be a
promising biomarker to predict a higher OS.
Combination therapy
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Background: Tumor specificcytotoxic T lymphocytes (CTLs) play a
pivotal role in cancer immunotherapies; however, their tumor-killing
efficacy is often stunted by immunosuppressive factors secreted in
the tumor microenvironment. Transforming growth factor-beta
(TGFβ) is one of the key immunosuppressive cytokines secreted that
attenuates the effector function of CTLs. Small molecule TGFβ kinase
inhibitors (TGFβi) may reverse immunosuppression and recover CTL
proliferation and effector functions. However, systemic delivery of
soluble TGFβi may cause severe toxicities given the pleiotropic na-
ture of TGFβ signaling. Strategies to selectively target TGFβi to CTLs
may significantly enhance therapy efficacy while reducing toxicities.
Materials and methods: We developeda T-cell targeted small mol-
ecule drug delivery platform based on amphiphilic gold nanoparti-
cles (amph-NPs). Amph-NPs [1,2] are composed of 3 nm gold cores
and coated by monolayers of 11-mercapto-1-undecanethiol sulfonate
(MUS) and octanethiol (OT) ligands. A small molecule TGFβi, SB525334,
was sequestered into the hydrophobic pockets of the alkanethiol lig-
and shell. To achieve in vivo T cell targeting, CD8 antibody fragments
were chemically conjugated to amph-NPs. To assess the effect of TGFβ
inhibition in CTLs on tumor progression, trivalent (gp100, trp1, trp2)
cancer vaccines [3] were given to B16F10 melanoma tumor-bearing
C57BL6 mice, followed by repeated dosing of systemic TGFβi, T-cell
targeted TGFβi or saline control.
Results: We previously showed that amph-NPs penetrate cell mem-
branes without causing transient pores or toxicity [1]. Further
mechanistic studies revealed that the flexibility of the organic li-
gands allows amph-NPs to embed within lipid bilayers and subse-
quently to transit across bilayers to enter cells [2]. Here we show
that we can sequester hydrophobic drugs like TGFβi in amph-NP
ligand shells and promote significantly enhanced drug uptake into
CD8+ T cells using the particles as a chaperone. By conjugating
amph-NPs with targeting antibodies or antibody fragments, we
transiently block their natural cell-penetrating behavior, enabling
targeted uptake into specific cells. In vivo, antibody-conjugated
amph-NPs increased CD8+ T cell targeting by 44-fold in spleen and
40-fold in blood 24 hours post intravenous administration. Ongoing
work focuses on testing therapeutic benefits of arming CTLs with
immunosuppressive-reverting drugs (TGFβi) along with a trivalent
cancer vaccine that elicits robust tumor specific CTLs.
Conclusions: We developed a T-cell targeted small molecule im-
munomodulator delivery platform that has potential to reverse
Journal for ImmunoTherapy of Cancer 2017, 5(Suppl 1):12 Page 15 of 19immunosuppression of lymphocytes caused by tumor microenvir-
onment, and ultimately achieve enhanced anti-tumor immunity
and better therapeutic outcome.
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Background: Based on their broad activation of the innate and
adaptive immune system TLR9 agonists are developed as anti-
cancer therapies. The dSLIM® family of TLR agonists consists of
covalently-closed dumbbell-shaped molecules acting as immune
surveillance reactivators (ISR) with a broad immunomodulatory po-
tential. One member of the dSLIM® family, lefitolimod (MGN1703),
is currently under evaluation in a phase 3 trial in mCRC patients
(IMPALA) and in clinical trials with other indications (e.g. patients
with small cell lung cancer/IMPULSE, patients with HIV infection/
TEACH). Another member, dSLIM2006, is presently in the preclinical
phase of development. The checkpoint inhibitor anti-PD-1 restores
T cell function especially of cytotoxic T cells and has the potential
to revert immune escape of tumor cells. Since the targets of TLR9
agonists are upstream of that of checkpoint inhibitor anti-PD-1, the
reactivation of the immune cells via TLR9 provides a basis for the
checkpoint inhibition and thus synergistic immunological effects
are expected in a combinatory approach.
Materials and methods: In preclinical development monotherapy
with lefitolimod reduced tumor growth in several murine tumor
models. For evaluation of the combinatory anti-tumor effect of lefito-
limod and anti-PD-1, a syngeneic murine tumor model using sub-
cutaneous (s.c.) inoculation of A20 cells (lymphoma) into Balb/c mice
was used. In addition, the combination strategy of dSLIM2006 with
anti-PD-1 was investigated in a colon carcinoma model utilizing s.c.
inoculation of CT26 cells into Balb/c mice. In these models, multiple
doses of lefitolimod or dSLIM2006, respectively, were given intratu-
morally (i.tu.) when tumor volume exceeded 100 mm3. Anti-PD-1 was
applied by the intraperitoneal (i.p.) route.
Results: Injection of anti-PD-1 as monotherapy had a moderate effect
on the tumor growth (tumor growth inhibition [TGI] = 20.3%) in the
colon carcinoma CT26 model. While injection of dSLIM2006 led to
moderate reduction of tumor growth (TGI = 32.1%) as well, treatment
of mice with a combination of dSLIM2006 and anti-PD-1 resulted in a
clearly increased TGI rate of 65.7% and statistically significant pro-
longed survival (p < 0.01). The combinatory effect of anti-PD-1 and
another member of the dSLIM® family, lefitolimod, was even more
pronounced: Injections of either anti-PD-1 or lefitolimod as mono-
therapy had a moderate anti-tumor effect (TGI = 45.9% and 49.8%,
respectively) in the A20 lymphoma model. However, the combined
treatment resulted in a clearly increased TGI of 99.1% and, conse-
quently, all mice treated with the combination survived (p < 0.001).
Conclusions: In conclusion, we showed that the immune surveillance
reactivators (ISR) lefitolimod and dSLIM2006, both members of dSLIM®
family of TLR9 agonists, enhance the limited anti-tumor effects of
checkpoint inhibitor anti-PD-1 in pilot studies in murine CT26 and A20
tumor models in vivo. These data show the promising potential for the
combination of TLR9 agonists with checkpoint inhibitors.A38
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Background: Lung Cancer due to high mortality is a problem of pub-
lic health worldwide. Adenocarcinoma is the most frequent histotype
and platinum-based double chemotherapy is employed as conven-
tional treatment. Several studies have reported that EGFR mutation-
positive patients treated with Tyrosine Kinase Inhibitors (TKI) have
better clinical outcomes than these patients treated with chemother-
apy. Erlotinib, a reversible TKI, induces in sensitive cell lines, cell cycle
arrest and apoptosis. These biological events are also induced by
Cisplatin (CDDP). Several reports indicate that some cytotoxic drugs
induce a new modality of cell death called immunogenic cell death
(ICD), which induces an antitumor immune response. The ICD re-
quires a spatial-temporal expression of three essential molecules
known as the hallmarks of ICD. An early event is the membrane ex-
position of calreticulin acting as “eat me” signal. Later, the release of
cytosolic ATP to the extracellular space, and the nuclear protein
HMGB1 outside the cell are required. Currently, no reports exist
whether Erlotinib and CDDP induces ICD in EGFR-mutated and wild
type lung cancer cell lines, respectively.
Materials and methods: Lung adenocarcinoma cell lines HCC827,
HCC4006 and A549 (EGFRwild type) were obtained from the ATCC.
Erlotinib was acquired from Sequoin and CDDP was obtained from
Sigma. Cells cultured in 96-well plates were treated with serial dilutions
of the compounds and cytostatic/cytotoxic effect was measured using
MTT assay. The HCC827 and HCC4006 were treated with Erlotinib for
48 h and the A549 cell line was treated with CDDP for 24 h and the
IC50was calculated. To study whether these cytotoxic drugs induces
ICD, drug concentration that induced around 80% of inhibition was
added to cell cultures. Cell death was evaluated by cell cycle analysis,
necrotic and apoptotic cells were quantified by annexin-V/propidium
iodide assay and fluorometry was used to evaluate whether apoptosis
is caspase 3-mediated. As ICD markers, the intracellular ADP/ATP ra-
tio (quantified by luminometry), HMGB1 (quantified by ELISA) and
membrane-exposed calreticulin (detected by flow cytometry and
immunofluorescence) were studied.
Results: In the HCC827 and HCC4006 cell lines, Erlotinib at low con-
centrations induced cell cycle arrest in G0/G1 phase. However, at high
concentrations, apoptosis (20%) mediated by caspase 3 activation, in-
crease of ADP/ATP ratio and of the HMGB1 release (only in HCC827)
was induced. No membrane-exposition of calreticulin was detected.
In A549 cells, CDDP induced apoptosis (40%) mediated by caspase 3
activation, increase of ADP/ATP ratio and of the release of HMGB1.
Membrane-exposed calreticulin was detected as spots.
Conclusions: In EGFR-mutated cell lines, Erlotinib-induced cell death
is not mediated by ICD. However, in the A549 cell line, CDDP induced
cell death mediated by ICD.
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Background: Advanced stage inoperable esophageal cancer has a
poor prognosis and patients rarely enjoy durable complete response
to treatment; progression free survival often is limited.
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of far advanced lung metastasis in triple negative breast cancer at
ITOC3 (Munich) 2016; here we report a similar successful treatment
concept. The patient was a 56-year-old male newly diagnosed with
adenocarcinoma of the esophagus with mediastinal lymphadenop-
athy. Histology revealed adenocarcinoma stage UICC IIIB T3 N2 with
disseminated mediastinal, para-esophageal and cervical lymph node
metastasis measuring up to 2.2 cm. HER-2/new score was positive.
The patient refused suggested neoadjuvant CHT with FLOT. Clinically
the patient presented with Karnofsky index of 90% with increasing
difficulties swallowing solid food and rapid weight loss of 6 kg in the
last 2 months. Therapy consisted of administration of the following
combination protocol: Low-dose PD-1 immune checkpoint (IC) inhibi-
tor nivolumab (0.5 mg/kg) with CTLA-4 IC inhibitor ipilimumab
(0.3 mg/kg) administered weekly, over three weeks. This was accom-
panied by loco regional hyperthermia with radiofrequency fields
(13.56 MHz) using the Syncrotherm device 3 times per week (max
output 400 w) over the tumor region in combination with high dose
vitamin C (0.5 g/kg) and alpha lipoic acid (600 mg) over three weeks.
This was followed by long duration fever range whole body
hyperthermia (using the Heckel device) in combination with low
dose chemotherapy using cyclophosphamide 300 mg/m2 to down
modulate Treg cells. Next, moderate dose i.v. interleukin 2 (IL-2) under
Taurolidine protection was administered for five days with careful
titration to daily fever hyperthermia of max 39.5 °C. Herceptin in a
dosage of only 4 mg/kg (patient refused higher dosage) was admin-
istered once.
Results: Unexpectedly, restaging 8 weeks following initiation of ther-
apy with Gastroesophagoscopy (Upper GI Endoscopy) revealed
complete response. This was confirmed by histological analysis of
multiple biopsies in the former tumour bed confirming complete
pathological response. At that time the patient had started gaining
weight again and was free of any cancer-related symptoms. Several
months later, he has regained 6 kg of weight, feels good, has no dys-
phagia, and continues to be monitored.
Conclusions: This is the second case of an advanced stage cancer
patient having a complete response to primary immunotherapy
treatment. Clearly, this combination immune treatment warrants
further clinical studies. The authors herewith confirm that they have
received consent from the patient to publish the data above.
A40
Doxorubicin loaded immunoliposomes coupled to anti-MAGE A1
TCR-like scFv for improved drug delivery to melanoma
Mesha Saeed1, Sara Zalba1, Reno Debets2, Timo L. M. ten Hagen1
1Laboratory of Experimental Surgical Oncology, Section Surgical
Oncology, Department of Surgery, Erasmus MC, Rotterdam, The
Netherlands; 2Laboratory of Tumor Immunology, Department of Medical
Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
Journal for ImmunoTherapy of Cancer 2016, 5(Suppl 1):A40
Background
In our previous research we have exploited T cell receptor (TCR) me-
diated targeting through single chain variable fragments coupled to
nanoparticles against melanoma. We showed that these melanoma
targeted immunoliposomes show exclusive binding to antigen posi-
tive melanoma cells. Here we deploy the targeted nanoparticles en-
capsulating drug to target melanoma as a proof of principle.
Melanoma is the deadliest form of skin cancer with increasing inci-
dence rates. In case of metastasis, survival rates decrease from 91 to
16%. It has already been shown in previous research that drug
loaded nanoparticles hold several advantages over free drugs. In our
previous research, we have shown that if these nanoparticles are
coupled to single chain variable fragments (scFv), against specific an-
tigens, selective tumor uptake can be increased. For this purpose,
concept of TCR-mediated targeting was exploited and scFv against
MHC restricted Cancer Testis Antigens (CTA) were used that mimic
TCR binding to MHC complex. The aim of this research is to formu-
late a targeted nanoparticle that can act as a multipurpose device,
maintaining its specificity to antigens expressed by tumor cells.Methodology
Anti-M1/A1 scFvs antibodies were produced, validated and coupled
to nanoparticles. Coupling was optimized and post coupling valid-
ation was also performed using various methods. Model drug doxo-
rubicin was actively loaded in liposomes prior to the coupling
process. Cytotoxicity assays were performed. To prove internalization
and binding of these targeted nanoparticles on melanoma cells, flow
cytometry and confocal microscopy were also performed. In vivo
pharmacokinetics and biodistribution was also performed in NMRI
nu/nu mice. In addition to this clinical efficacy and general toxicity
was also studied.
Results:
In vitro experiments show higher binding and internalization of
immunoliposomes to antigen-positive B cells as well as M1/A1-posi-
tive melanoma cells, in comparison with non-targeted liposomes.
Cytotoxicity assays showed a significant difference between targeted
and nontargeted liposomal doxorubicin efficacy on M1/A1 expressing
tumor cells but not on negative cells. In vivo pharmacokinetics study
show, immunoliposomes are cleared a bit faster but not significantly
different than non-targeted liposomes. Clinical efficacy showed slight
toxicity in the targeted liposomes groups but higher anti-tumor activ-
ity as well in comparison to control groups. Biodistribution study
showed higher drug levels in tumors when treated with targeted li-
posomes. Clinical efficacy showed a better survival and delayed
tumor growth in targeted liposomal doxorubicin group.
Conclusion:
Targeted formulations retained 90% of the drug as well as the non-
targeted formulation. Blood residence time was slightly less than
non-targeted liposomes but accumulation of these targeted lipo-
somes in tumor is high. Bioavailability of the drug can be improved
by these drug loaded targeted nanoparticles. Better retention time of
drug together with increased availability in tumor provides a plat-
form for multiple purposes such as drug deliver, imaging and carry-
ing other therapeutic molecules.
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Background: The purinergic P2X7 receptor is an ATP-gated cation
channel expressed by hematopoietic as well as by many tumor cells.
Expression of P2X7 provides a growth advantage for tumor cells by
increasing mitochondrial calcium content and stimulating cell metab-
olism. On the other hand, strong stimulation of P2X7 can cause
death of tumor cells, and expression of P2X7 by host immune cells is
detrimental to the tumor by enhancing the anti-tumor immune re-
sponse. Little is known about the role of P2X7 in the context of
chemotherapy. We therefore studied the effects of P2X7 stimulation
on the in vitro toxicity of Doxorubicin (DXR) in Yac-1 lymphoma cells
that express P2X7 endogenously and also in several cell lines, trans-
duced with P2X7 variants.
Materials and methods: P2X7 mediated ectodomain shedding, PS
exposure and pore formation were monitored by flow cytometry.
Doxorubicin and ATP toxicity were observed by flow cytometry and
acid phosphatase assay in lymphoma and solid tumor cell lines.
Results: Low doses of extracellular ATP (eATP) that caused little toxicity
by themselves enhanced sensitivity to DXR by 7 to 8 fold. Transient
exposure to eATP and DXR for one hour was sufficient to induce cell
death after overnight culture. Mechanistically, gating of P2X7 aug-
mented the initial uptake of DXR into cells. However, enhanced cell
death was also observed even when DXR was washed away before ex-
posure to eATP, indicating that this was not the only mechanism and
suggesting that the synergism was rather due to an interaction of
downstream signaling pathways. The synergism of ATP and DXR was
enhanced by an agonistic nanobody to P2X7. Sensitization to DXR by
eATP was also observed after transfection of P2X7 into several other
Journal for ImmunoTherapy of Cancer 2017, 5(Suppl 1):12 Page 17 of 19tumor cell lines that do not express P2X7 endogenously. In these exper-
iments we observed that sensitization to DXR was linked to a specific
splice variant (P2X7k) of P2X7.
Conclusions: Our results show that P2X7 on tumor cells may contribute
to the success of chemotherapy, and suggest modulation of P2X7 as a
therapeutic strategy to enhance the cytotoxicity of chemotherapeutic
drugs.
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Background: Trabectedin has direct cytotoxic activity in tumor cells
and has also been shown to deplete pro-tumor macrophages in the
tumor microenvironment (Germano et al., Cancer Cell 2013). Nivolumab
inhibits the immune checkpoint molecule, PD-1, which restores anti-
tumor activity in tumor-infiltrating T cells. The guiding hypothesis is
that the combination of trabectedin and anti-PD-1 therapy synergistic-
ally attacks tumor cells and promotes anti-tumor immunity. The objec-
tives are to assess the safety/toxicity and efficacy of sequential
administration of trabectedin and nivolumab in patients with advanced
soft tissue sarcoma (STS).
Materials and methods: Fourteen patients with locally-advanced and/
or metastatic STS were evaluated. Each patient received 1 dose of
single-agent trabectedin (1.5 mg/kg continuous intravenous infusion,
CIV, for 24 hours), followed by sequential administration of trabectedin
CIV and nivolumab (3 mg/kg IV over 30 minutes) every 3–4 weeks,
starting 3 weeks after the first trabectedin dose. Safety/toxicity was ana-
lyzed using the NIH/NCI CTCAE v.4.03. Baseline and follow-up CT scans
or MRIs were performed after every 2 cycles of the sequential chemo-/
immuno-therapy. Tumor responses were assessed by RECIST v1.1 and
immune-related response criteria (irRC).
Results: Histologic subtypes include malignant fibrous histiocytoma/
undifferentiated pleomorphic sarcoma (n = 6), leiomyosarcoma (n = 3),
synovial sarcoma (n = 2), myxoid liposarcoma (n = 2) and chondrosar-
coma (n = 1). All patients had metastatic disease and a median of 4
lines of prior chemotherapy. Safety analysis: Grade 3 treatment emer-
gent adverse events include anemia (n = 1), fatigue (n = 1), decreased
platelet count (n = 1), and increased creatine kinase (n = 1). No
immune-related adverse event has been observed so far. Efficacy ana-
lysis: Thirteen patients received 2 cycles of sequential chemo-/immuno-
therapy, had follow-up CT scan or MRI, and were evaluated for object-
ive response (OR), best overall response rate, (BORR), disease control
rate (DCR), progression-free survival (PFS) and overall survival (OS).
There were 2 partial responses (PR), 8 stable disease (SD) and 3 pro-
gressive disease (PD), with best overall response rate (BORR) of 15.3%,
DCR of 76.9%, median PFS of >24 weeks (range: 8- > 24 weeks), median
OS of >24 weeks (12.3- > 24 weeks), 6 month PFS rate of 69%, and
6 month OS rate of 92%. Six-month OS rate for all 14 patients was 86%.
Conclusions: Taken together, the results suggest that paired adminis-
tration of trabectedin and nivolumab is safe, and that this chemo-/
immuno-therapy approach has synergistic activity.
Anti-cancer vaccines
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partner HER2 are extensively characterized oncogenes and highly val-
idated targets for cancer therapy. However, monotherapies against
one of these receptors are hampering since resistance appearance,
some associated with upregulation of other members of HER family.
Then combined therapies using monoclonal antibodies (MAbs) and
tyrosine kinase inhibitors (TKI) have been suggested as a promising
strategy to circumvent resistance. We propose an alternative strategy
based on simultaneous inactivation of HER1 and HER2 by multi-
epitope targeting trough specific polyclonal antibodies (PAbs) in-
duced by vaccination.
Materials and methods: PAbs were generated by immunizing mice
with 400 μg of HER1 and HER2 extracellular domains adjuvated in a
very small size proteoliposome (VSSP) derived from the outer mem-
brane of Neisseria meningitides. Viability assays were performed by
MTT assay, proteins expression was evaluated by flow cytometry and
western blot.
Results: Elicited PAbs blocked receptors activation and provoked
their abrupt degradation, conducing to down-signaling cascades in-
hibition. This effect was translated in proliferation arrest and apop-
tosis induction of tumor cells. Despite the differences in expression
levels of HER1 and HER2 in the tested tumor lines, PAbs showed
cytotoxicity in all of them, and the highest effect was obtained on
cells with lower expression of both receptors.
Conclusions: These new insights will contribute to a rational design
of HER family targeting multivalent vaccines as an encouraging ap-
proach for cancer patient’s treatment.
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Background: Despite being quite effective, conventional cancer ther-
apies have the major drawback of triggering numerous side effects.
Currently, a challenging goal in this area is the development of in-
novative targeted antitumor immunotherapy with a long-term effi-
ciency. In this context, our team took advantage of liposomal
nanoparticle properties for the conception of cancer vaccines, which
contain all the elements needed for the induction of an efficient anti-
tumor immune response i) a peptide able to activate CD4+ T helper
cells ii) a tumor peptide expressed by the cancer cells, recognized by
CD8+ T cytotoxic cells and iii) Toll or Nod-Like receptor (TLR and NLR)
ligand which act as adjuvants for the activation of the innate im-
mune response. The aim of our project is to conceive liposomal vac-
cines, which would be effective even against tumors in later stage.
Materials and methods: Different vaccines formulations containing
the three types of components have been designed and compared
for their capacity to induce a strong immune response associated
with antitumor activity in vivo. C57BL/6 J mice were injected in the
tail vein with tumor cells (TC-1 cell line) expressing the E7 peptide,
leading to the development of pulmonary tumor nodules. Then, in-
jections of liposome-based vaccines were performed subcutaneous-
lyat different times after tumor implantation. One month later, lung
tumor nodules are counted and the spleen and lymph nodes are har-
vested to perform an IFN-γ ELISpot assay against tumor cell epitopes
to measure the number of tumor specific T cell.
Results: We evaluated three liposomal vaccines which contained the
same T CD4+ and T CD8+ specific peptides but a different adjuvant.
Formulations containing either ligand of TLR 2/6, ligand of TLR4 or
ligand of NOD1 were able to induce a strong immune response and
a good antitumor effect in vivo in mice grafted with pulmonary tu-
mors. We observed an almost complete inhibition of tumor growth-
after vaccine injections on days 2 and 4 after tumor implantation.
Liposomes containing the NOD-1 ligand showed the most promising
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after tumor implantation. To increase this therapeutic delay, we
combined in the same nanoparticles TLR2/6 and NOD1 ligands.
Surprisingly, although liposomes containing the NOD1 ligand
alone induced an almost complete regression of tumors (99%)
when injected at day 8 and 10 after tumor implantation, TLR2/6
and NOD1 ligand association allowed only a decrease in tumor
growth of 60%.
Conclusions: To continue improving the efficacy of our treatment,
we will test other combinations of TLR and NLR ligands in order to
induce a synergistic effect. We also plan to address liposomes to
immune cells by adding on nanoparticles a mannosylated ligand
(which will be recognized via mannose receptor expressed by im-
mune cells).
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Background: Photochemical Internalisation (PCI) is a technology for
inducing cytosolic delivery of endocytosed molecules by illumination.
This is a principle (fimaVacc technology) that can be used for enhan-
cing CTL responses; re-routing antigen presentation from MHC class
II to MHC Class I by making access for the antigen to the MHC Class I
presentation machinery in the cytosol of APCs. In the fimaVacc tech-
nology a photosensitising molecule (fimaporfin (TPCS2a)) is used to
make endocytic membranes light sensitive, with illumination indu-
cing permeabilisation of the membranes. The photochemical treat-
ment also induced local inflammation that may also enhance CD4 T
cell and antibody responses to vaccines.
Methods: Preclinical studies with fimaVacc has been shown to in-
crease MHC class I antigen presentation and CTL responses in vari-
ous mouse models; in addition with several antigens also helper T-
cell humoral immune responses are enhanced. FimaVacc involves
formulating the vaccine with fimaporfin and since peptide antigens
are poorly immunogenic by themselves, an additional adjuvant is
often used to induce an appropriate immune response. The fimaVACC
technology has shown synergy with several adjuvants such as MPLA,
poly-IC and poly-ICLC, in enhancing both cellular and humoral immune
responses. A phase I clinical study with fimaVACC is ongoing in healthy
volunteers in the United Kingdom. The subjects are vaccinated (up to
three occasions) with models for peptide- and protein-based vaccines;
HPV16 E7 peptide antigens and Keyhole Limpet Hemocyanin, using the
TLR3 agonist poly-ICLC (Hiltonol) as adjuvant. The vaccine is as intrader-
mal injections followed by illumination of the vaccination site. Local
and systemic adverse effects will be assessed, and cellular and humoral
immune responses will be analysed by ELISPOT and ELISA assays,
respectively.
Results: The principle of the fimaVacc technology will be presented,
together with preclinical results showing that the fimaVacc strongly
and synergistically enhances both cellular and humoral immune re-
sponses when given with several types of adjuvants including MPLA,
poly-IC, Ploy-ICLC and gm-CSF. Data showing enhancement of TNF-α
and INF-γ cytokine production from both CD4- and CD8+ T cells, and
the improvement of anti-tumour effects in different clinically relevant
mouse models, will be presented.
Further, the design of the ongoing clinical study, and initial clinical
results will be presented.
Conclusions: The fimaVacc technology strongly enhances the effect
of therapeutic cancer vaccines in pre-clinical models and strong syn-
ergy is observed with several types of adjuvants. A phase I study in
healthy volunteers is currently ongoing in the UK to assess the PCI
technology for vaccination in humans.PCI has a completely novel mechanism of action as a vaccination
technology, representing a potent tool for stimulation of cytotoxic
CD8 T-cell responses, CD4 T-cell responses as well as antibody
production.
PCI can give strong synergy with commonly used immunological
adjuvants.
A46
An Immunoinformatics Framework for Identification of
Personalized Tumor Epitopes in Cancer
T. Jaitly1, J. Dörrie1, N. Schaft1, S. Gross1, B. Schuler-Thurner1, S. Gupta2, L.
Taher3, G. Schuler1, J. Vera1
1Fredrich Alexander University Hospital, Erlangen, Germany; 2University
of Rostock, Rostock, Germany; 3Fredrich Alexander University, Erlangen,
Germany
Correspondence: T. Jaitly
Journal for ImmunoTherapy of Cancer 2016, 5(Suppl 1):A46
Background: Tailor-made therapeutic vaccines is a promising approach
to fight solid tumors based on individual patient’s genomics and tran-
scriptomics profile. These personalized vaccines are actively tailored
based on individual’s tumor characteristics obtained from tumor sam-
ples after surgery. A remarkable case is dendritic cell-based vaccination,
an immunotherapy in which tumor epitopes targeting patient’s specific
mutations are used to prime DCs, which helps in stimulating cytotoxic
T cell mediated anticancer immunity once intravenously injected.
Materials and methods: Here we present an immunoinformatics
framework for personalized identification of tumor epitopes using
patient specific haplotype and mutation profiles. In the framework
proposed, we analyze whole exome sequencing and RNA sequencing
patient data to detect patient specific mutations and their expression
level. Epitopes including the tumor mutations are computationally
predicted using patient’s haplotype and filtered based on their expres-
sion level, binding affinity, tumor Variant Alelle Frequency and tumor
clonality. Epitopes are further selected by calculating minimization en-
ergy for epitopes using molecular dynamics simulation.
Results: We predicted tumor epitopes for patients with metastatic
cancer. Out of 1080 epitopes only 20 best epitopes were selected for
molecular dynamics simulations to select top 10 best epitopes. These
best epitopes are under experimental validation.
Conclusions: Our pipeline is able to predict tumor epitopes in more
automatic and personalized manner.
Adoptive cell therapy
A47
Preclinical characterization of a PD-1-CD28 fusion receptor for T
cell-based immunotherapy of Non-Hodgkin Lymphoma
F. Rataj, F. Kraus, S. Grassmann, M. Chaloupka, S. Lesch, C. Heise, S.
Endres, S. Kobold
Center of Integrated Protein Science Munich (CIPS-M) and Division of
Clinical Pharmacology, Department of Internal Medicine IV, Klinikum der
Universität München, Munich, Germany, Member of the German Center
for Lung Research, Munich, Germany
Correspondence: F. Rataj
Journal for ImmunoTherapy of Cancer 2016, 5(Suppl 1):A47
Background: Interaction of the Programmed Death Receptor 1 (PD-1)
and its ligand, PD-L1, has been shown to suppress T cell activity and
allows tumors to evade T cell mediated immune-response. Our group
recently showed that antigen-specific T cells transduced with a PD-1-
CD28 fusion receptor are protected from PD-1-mediated inhibition.
These cells are co-stimulated via CD28 signalling, resulting in tumor-
rejections in a murine model of pancreatic cancer. The following
study aims to proof the potential of PD-1-CD28 fusion receptor trans-
duced T cells for immunotherapy of Non-Hodgkin-Lymphoma.
Materials and methods: Murine PD-L1 was retrovirally transduced
into ovalbumine (OVA)-overexpressing murine T cell lymphoma cells
(EG7). OVA-specific CD8+ were retrovirally transduced with PD-1-
CD28 fusion receptor. Cytokine release, proliferation and cytotoxic
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were determined in vitro. Anti-tumor effect of PD-1-CD28 expressing
T cells was analysed in EG7-PD-L1 tumor bearing C57Bl/6 mice.
Results: In vitro co-culture of PD-1-CD28 fusion receptor transduced T
cells and EG7-PD-L1 tumor cells induced specific T cell activation mea-
sured by IFN-y release (p < 0.001). T cell-induced lysis of target cells was
increased (three-fold induction) upon PD-L1 binding. In vivo treatment
of subcutaneous EG7-PD-L1 tumor-bearing mice with transduced T
cells resulted in a delayed tumor growth associated with complete
tumor regressions in 40% of all mice compared to control groups.
Cured mice were protected upon subsequent rechallenge with EG7-
PD-L1 tumors, suggesting a memory response and epitope spreading.
Conclusions: Our results indicate that adoptively transferred PD-1-
CD28-transduced T cells have the potential to overcome the PD-1-
PD-L1 immunosuppressive axis in Non-Hodgkin-Lymphoma.
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Background: Adoptive T cell transfer (ACT) with tumor-specific cyto-
toxic T lymphocytes is a promising treatment modality for a number
of malignancies. However, so far, the success of ACT in solid tumors
is poor. The lack of efficacy of ACT in solid entities is in part due to
tumor-microenvironment induced T cell exhaustion and anergy.Tumor Growth Factor - β (TGF-β) is produced in large amounts by
pancreatic cancer cells and their surroundings and is thought to sup-
press T cell activity through binding to the ubiquitously expressed
TGF-β receptor-1 and −2 tetramers. We hypothesize that a truncated
TGF-β-receptor may shield T cells from TGF-β effects.
Materials and methods: As the segment responsible for TGF-
βsignaling resides in the intracellular domain of the TGF-β Receptor
2 (TGF-β-R2), a stop codon has been inserted after the tenth intracel-
lular amino acid to prevent further translation, this receptor is also
known as Dominant Negative TGF-β-R2 (DNR). The product was then
cloned in the pMP71 retroviral vector. The generated receptor can
be constitutively expressed in T cells upon transduction and com-
petes with the endogenous TGF-β R2 for the formation of tetramer
receptor complexes. We have expressed the DNR through retroviral
transduction in primary murine T cells specific for the model antigen
ovalbumin (OT-1 cells) and tested the transduced cells in vitro with
cultures in the presence of TGF-β and in vivo as treatment for Pan-
c02OVA subcutaneous tumors.
Results: When cultivated with TGF-β, DNR transduced cells are un-
affected by TGF-β in terms of proliferation, as opposed to untrans-
duced cells which stop proliferating in the presence of TGF-β. This is
mirrored by undetectable phosphorylation of SMAD2/3 complexes in
DNR T cells as opposed to untransduced T cells upon TGF-β addition.
In vivo, ACT of DNR transduced cells in mice bearing Panc02OVA tu-
mors, ameliorates tumor control and overall survival compared to
untransduced OT1 T cells.
Conclusions: Adoptive T cell therapy efficacy can be improved in a
pancreatic cancer model by introducing a Dominant Negative TGF-β
Receptor 2 into antigen-specific T cells. This receptor may be com-
bined with other promising strategies to improve the efficacy of cel-
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